Section 35

EurekaMag Full Text Articles Chapter 34,335


Piscione, T.D.; Cella, C.; Hu, M.; Rosenblum, N.D. 2002: ALK3 and SMAD4 regulate collecting duct morphogenesis in vivo. Pediatric Research 51(4 Part 2): 53A
Gaussin, V.; Morley, G.; Liu, J.; Cox, L.; Hong, C.; Depre, C.; Myers, D.; Mishina, Y.; Behringer, R.; Hanks, M.; Zwijsen, A.; Huylebroeck, D.; Fishman, G.; Schneider, M.; Burch, J.; Vatner, S. 2004: ALK3 is necessary for atrio-ventricular conduction system development. FASEB Journal 18(4-5): Abstract 307
Gaussin, V.; Liu, J.; Mishina, Y.; Hanks, M.C.; Schneider, M.D.; Burch, J.B. 2003: ALK3-dependent mechanism regulating atrio-ventricular valve development. Circulation 108(17): IV141
Laping, N.J.; Grygielko, E.T.; Thornton, P. 2003: ALK5 inhibition and ACE inhibition reduce matrix markers in diabetic rat kidneys. FASEB Journal 17(4-5): Abstract 569
See, F.; Tzanidis, A.; Krum, H. 2003: ALK5 inhibition attenuates TGFbeta1-induced collagen production by rat cardiac fibroblasts Implications for cardiac remodeling. Circulation 108(17): IV245
Laping, N.J. 2003: ALK5 inhibition in renal disease. Current Opinion in Pharmacology 3(2): 204-208
Owens, J.M.; Hattersley, G.; Lyons, K.; Rosen, V. 2000: ALK6, a type I BMP receptor, is not required for endochondral bone formation. Journal of Bone and Mineral Research 15(Suppl 1): S203
Krauze, A.; Matysiak, M.; Krenke, K. 2001: ALL HRG Experience with modified New York Regimen. Annals of Hematology 80(Suppl 2): S26
Gueller, S.; Beissert, T.; Komor, M.; Schneider, O.; Henschler, R.; Hoelzer, D.; Ottmann, O.G.; Hofmann, W.K.; Ruthardt, M. 2002: ALL-Associated p185 and CML-Associated p210 BCR-ABL Induce a Nearly Identical Gene-Expression Profile In Vivo. Blood 100(11): Abstract No. 1211
Alderman, M.H. 2003: ALLHAT and beyond. American Journal of Hypertension 16(6): 512-514
Lanthier, L.; Nawar, T.; Plante, G.E. 2003: ALLHAT study Towards a unique therapeutic approach of hypertension. M-S (Medecine Sciences) 19(3): 377-380
Ciana, G.; Tamaro, G.; Martini, C.; Ceschel, S.; Cuttini, M.; Bembi, B. 2000: ALP isoenzyme separation in type 1 Gaucher disease. Clinical Chemistry and Laboratory Medicine 38(5): 479-480
Mathews, C.E.; Graser, R.T.; Serreze, D.V.; Leiter, E.H. 1999: ALR/Lt mice beta cell resistance to chemical and autoimmune attack associated with increased anti-oxidant defenses. Diabetes 48(Suppl 1): A450-A451
Couratier, P.; Keita, M.; Magy, L.; Vallat, J.M.chel 2000: ALS CSF is neurotoxic on spinal motoneuron/glial cell cultures. Neurology 54(7 Supp 3): A306
Galasko, D.R.; Plato, C.C.; Garruto, R.M.; Gamst, A.; Craig, U.K.; Torres, J.; Wiederholt, W.C. 2001: ALS and Parkinson-Dementia complex of Guam A 40-year follow-up of a prospective case-control study. Neurology 56(8 Suppl 3): A115-A116
Restivo, D.A.; Bianconi, C.; Ravenni, R.; De Grandis, D. 2000: ALS and myasthenia: An unusual association in a patient treated with riluzole. Muscle and Nerve 23(2): 294-295
McDermott, M.P.; Rowland, L.P. 2001: ALS defeats gabapentin: reflections on another failed treatment. Neurology 56(7): 826-827
Aoki, M.; Nagai, M.; Kato, M.; Itoyama, Y. 2001: ALS models by transgenic animals. No to Shinkei 53(9): 799-807
Anonymous 2004: ALS resistance testing puts situation into perspective. International Pest Control 46(3): 157
Banack, S.A.; Cox, P.A.; Monson, C.S. 2002: ALS-PDC and flying fox declines in Guam Linkage of a human health crisis to wildlife extinction. Ecological Society of America Annual Meeting Abstracts 87: 69
Kruman, I.I.; Camandola, S.; Thellung, S.; Luo, H.; Mattson, M.P. 1999: ALS-linked Cu/Zn-SOD mutation induces mitochondrial dysfunction and disturbance of calcium homeostasis. Society for Neuroscience Abstracts 25(1-2): 1835
Kruman, I.I.; Pedersen, W.; Mattson, M.P. 1999: ALS-linked mutation in human Cu/Zn-SOD enhances vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Journal of Neurochemistry 72(Suppl ): S20
Jones, R.; Pembrey, M.; Golding, J.; Alspac Study Team 2001: ALSPAC, a prospective longitudinal population-based study of common outcomes and diseases. Human Mutation 17(4): 334
Dhanji, T.A.; Davies, V.L.; Armon, C.; Moses, D.E.; Britt, W.G.IIi; Graves, M.C.; Forte, D.K.; Sepulveda, L.; Cwik, V.; Lindsey, B.; Shamel, M.; Smith, R.A. 2000: ALSQOL-11-A short, subjective, disease-specific, quality-of-life scale for patients with ALS Sensitivity to change. Neurology 54(7 Supp 3): A344
Panagiotopoulos, S.; Forbes, J.M.; Soulis, T.; Thallas, V.; Long, D.; Jerums, G.; Cooper, M.E. 2000: ALT 946, a novel inhibitor of advanced glycation, prevents albuminuria in experimental diabetes. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 650A
Box, T.D.; Boschert, M.E.; Bowers, J.H.; Hutson, W.R.; Thomason, I.R.; Christiansen, J.E.; Rose, K.; Gaglio, P. 2000: ALT Flare with daily Infergen treatment of chronic hepatitis C. Hepatology 32(4 Pt 2): 566A
Ribeiro, R.M.; Layden, J.E.; Siadat, M.; Layden, T.J.; Perelson, A.S. 2002: ALT dynamics during IFN treatment of HCV infected patients. Hepatology 36(4 Part 2): 293A
Box, T.D.; Boschert, M.E.; Bowers, J.H.; Desautels, S.G.; Hutson, W.R.; Thomason, I.R.; Christiansen, J.E.; Rose, K.; Gaglio, P.J. 2000: ALT elevation with interferon induction therapy A comparison of Intron A vs Infergen. Gastroenterology 118(4 Suppl 2 Pt 2): AASLD A142
Cooksley, W.G. E.; Lai, M.Y.; Piratvisuth, T.; Wang, Y.J.; Mahachai, V.; Chao, Y.C.; Tanwandee, T.; Chutaputti, A.; Chang, W.Y.; Zahm, F.E.; Pluck, N. 2003: ALT flares in patients with HBeAg-positive chronic hepatitis B and treated with either conventional interferon alfa-2a or peginterferon alfa-2a are not necessary for a significant response to therapy. Hepatology 38(4 Suppl 1): 724A
Hann, H.W.L.; Funk, M.L.; Rosenberg, D.M.; Hawley, S.; Davis, R. 2001: ALT normalization and loss of HBV DNA among HBeAg negative hepatitis B patients treated with lamivudine in a clinic setting. Journal of Hepatology 34(Suppl 1): 160
Hudson, V.W.; Chang, H.F.; Mashayekhi, B. 2003: ALTBIB Alternatives to Animal Testing Database. Toxicological Sciences 72(S-1): 219
Mastana, S.S.; Papiha, S.S.; Singh, P.; Singh, M.; Das, K.; Pacynko, A.; Fisher, P.; Das, M.; Malik, N.; Reddy, P. 2002: ALU genetic diversity in British and Indian populations. European Journal of Human Genetics 10(Suppl 1): 186
Mastana, S.S.; Papiha, S.S.; Singh, P.; Das, K.; Pacynko, A.; Fisher, P.; Malik, N.; Das, M.; Reddy, P.H. 2000: ALU genetic diversity in Indian populations. American Journal of Human Genetics 67(4 Suppl 2): 236
Demchyshyn, L.L.; Colantonio, C.M.; Liao, L.; Burrowes, C.; Yang, Z.J. 2001: ALX-0600 A potent glucagon-like peptide-2 receptor agonist. Gastroenterology 120(5 Suppl 1): A 509
Jeppesen, P.B.; Blosch, C.M.; Lopansri, J.B.; Sanguinetti, E.L.; Buchman, A.L.; Scolapio, J.L.; Ziegler, T.R.; Howard, L.; Mortensen, P.B. 2002: ALX-0600, a dipeptidyl peptidase-IV resistant glucagon-like peptide-2 analog, improves intestinal function in short bowel syndrome patients with a jejunostomy. Gastroenterology 122(4 Suppl 1): A-191-A-192
Sorbera, L.A.; Leeson, P.A. 2000: ALX1-11 Treatment of osteoporosis. Drugs of the Future 25(10): 1007-1010
Sun, J. 2003: AM/PM menopausal formula relives menopausal symptoms a pilot study. FASEB Journal 17(4-5): Abstract 692
Kempkes Koch, M.; Fobker, M.; Gerhardt, U.; Suwelack, B.M.; Hohage, H. 2000: AM19 metabolite as a potential biomarker in urine for CsA nephropathy. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 720A
Ramos, A.; Lopez, A.; Talamas, P.; Rosales, J.L. 1999: AM230 of Trypanosoma cruzi induced nitric oxide production by macrophages. American Journal of Tropical Medicine and Hygiene 61(3 Suppl): 263
Villarrubia, V.; Reyes, E.; Alvarez Mon, M. 2002: AM3 normalizes transaminases levels in animal models and in patients with acquired or iatrogenically-induced liver pathologies. Hepatology 36(4 Part 2): 627A
Feld, J.; Heathcote, J. 2002: AMA positive autoimmune hepatitis does not equal AIH/PBC overlap syndrome. Hepatology 36(4 Part 2): 506A
Norton, R.S.; Feng, Z.P.; Evans Stevenson, R.A.; Keizer, D.W.; Yao, S.; Murphy, V.; Coley, A.; Foley, M.; Anders, R.F. 2003: AMA1 from Plasmodium falciparum 3D structure and interactions. Experimental Parasitology 105(1): 10
Zha, Shan; Ferdinandusse, Sacha; Wanders, Ronald J.A.; Luo, Jun; De Marzo, Angelo M.; Isaacs, William B. 2003: AMACR as a new therapeutic target in prostate cancer. Proceedings of the American Association for Cancer Research 44: 192
Gunga, H.C.; Kirsch, K.; Koralewski, E.; Boldt, L.E.; Roecker, L.; Johannes, B.; Fries, D.; Humpeler, E.; Schobersberger, W. 2001: AMAS - 2000 Fluid distribution and tissue thickness changes at moderate altitude in patients with metabolic syndrome. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R233
Riedmann, B.; Riedmann, G.; Waanders, R.; Fries, D.; Humpeler, E.; Gunga, H.C.; Schobersberger, W. 2001: AMAS - 2000 Wellbeing and cognitive performance of patients with a metabolic syndrome during a three-week stay at moderate altitude. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R231
Humpeler, E.; Gunga, H.C.; Schobersberger, W. 2001: AMAS-2000 A research project on holiday medicine and altitude acclimatisation. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R231
Fries, D.; Humpeler, E.; Mittermayr, M.; Klingler, A.; Gunga, H.C.; Jelkmann, W.; Schobersberger, W. 2001: AMAS-2000 Erythropoiesis and iron metabolism in patients with the metabolic syndrome at moderate altitude. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R232
Lechleitner, M.; Humpeler, E.; Schobersberger, W.; Gunga, H.C.; Hoppichler, F. 2001: AMAS-2000 Metabolic improvement in overweight men exposed to moderate altitude. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R232
Schmid, P.; Humpeler, E.; Schobersberger, W.; Baumgartner, H.; Hoertnagl, H.; Gunga, H.C.; Klingler, A.; Fries, D.; Spiesberger, R.; Pokan, R. 2001: AMAS-2000 Physical capacity and blood pressure response before, during and 6 weeks after a three weeks stay at moderate altitude in patients with metabolic syndrome. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R231
Schmid, P.; Humpeler, E.; Schobersberger, W.; Klingler, A.; Hoertnagl, H.; Gunga, H.C.; Fries, D.; Spiesberger, R.; Pokan, R. 2001: AMAS-2000 Twenty-four hour blood pressure and pulse rate monitoring in patients with the metabolic syndrome at moderate altitude. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R232
Sun, W.; Li, F.; Zhao, K.; Wang, J.; Gao, Y. 2003: AMASS, a bioinformatic tool for validation of SEQUEST search results by automatic screening of its ion maps. Molecular and Cellular Proteomics 2(9): 829
Iwakura, A.; Yamaguchi, J.; Luedemann, C.; Asahara, T.; Losordo, D.; Bridger, G. 2002: AMD-3100, a CXCR4 Antagonist, Augments Incorporation of Bone Marrrow-Derived Eendothelial Progenitor Cells into Sites of Myocardial Neovascularization. Blood 100(11): Abstract No. 1127
Broxmeyer, H.; Cooper, S.; Hangoc, G.; Bridger, G. 2002: AMD-3100, an antagonist of CXCR4, is a potent myeloid progenitor cell mobilizing agent in mouse strains differing in response to G-CSF-induced mobilization, and synergizes with G-CSF in these mice to enhance mobilization. Experimental Hematology (Charlottesville) 30(6 Suppl 1): 45
Flomenberg, N.; Dipersio, J.; Liesveld, J.; Mccarty, J.; Rowley, S.; Vesole, D.; Badel, K.; Calandra, G. 2003: AMD3100+G-CSF hematopoietic progenitor cell mobilization is safe, effective, and superior to mobilization with G-CSF alone. Blood 102(11): 39a
Iwakura, A.; Luedemann, C.; Kusano, K.; Takenaka, H.; Eaton, E.; Bridger, G.; Losordo, D.W. 2003: AMD3100, a CXCR4 antagonist, augments mobilization and incorporation of bone marrow-derived endothelial progenitor cells into sites of myocardial neovascularization. Circulation 108(17): IV159
Broxmeyer, H.E.; Hangoc, G.; Cooper, S.; Li, X.; Bridger, G.; Clapp, D.W.de 2002: AMD3100, an Antagonist of CXCR4 and Mobilizer of Myeloid Progenitor Cells, Is a Potent Mobilizer of Competitive Repopulating Long Term Marrow Self-Renewing Stem Cells in Mice. Blood 100(11): Abstract No. 2397
Devine, S.M.; Liu, F.; Holt, M.; Link, D.; Dipersio, J.F. 2003: AMD3100-mobilized murine hematopoietic stem cells and T-lymphocytes have identical capacity to induce multilineage stem cell engraftment, donor T-cell chimerism and GVHD in mice compared with G-CSF mobilized cells. Blood 102(11): 938a-939a
Giandomenico, C.M. 2003: AMD473, the next generation of orally active platinum anticancer agent. Abstracts of Papers American Chemical Society 226(1-2): INOR 358
Sharov, A.I. 2002: AMETHYST project overview. Berichte zur Polar- und Meeresforschung 413: 55-64
Brenner, B.M. 2003: AMGEN International Prize: the history and future of renoprotection. Kidney International 64(4): 1163-1168
Hair, W.M.; Riley, S.C.; Groome, N.P.; Wu, F.C.W.; Lincoln, G.A. 2001: AMH and inhibin beta as markers of Sertoli cell function during a steroid based hormonal contraceptive regime in men. Journal of Andrology (Suppl): 156
Mccoy, A.K. 2000: AMI in the elderly Variation in treatment choice and outcome. Circulation 102(18): 2; 851
Wu, M.; Zhai, Z.H.; Shu, H.B.n 2002: AMID, an AIF homologous protein, induces caspases-independent apoptosis. Cell Research 12(3-4): 295
Alyea, E.P.; Kim, H.T.; Cutler, C.; Ho, V.; Lee, S.J.; Parik, B.; Windawi, S.; Deangelo, D.; Stone, R.M.; Ritz, J.; Antin, J.H.; Soiffer, R.J. 2003: AML and MDS treated with nonmyeloablative stem cell transplantation Overall and progression free survival comparable to myeloablative transplantation. Blood 102(11): 79a
Lowenberg, B. 2001: AML biology in a clinical perspective. Annals of Hematology 80(Suppl 2): S5
Voliotis, D.; Horn, P.A.; Staib, P.; Diehl, V.; Engert, A. 2001: AML blasts frequently express early B-cell antigen CD79a Is there a need for changing the EGIL classification?. Annals of Hematology 80(Suppl 2): S23
Estey, E.; Beran, M.; Koller, C.; Freireich, E. 1999: AML in elderly patients. Annals of Hematology 78(Suppl 2): S17
Bassan, R.; Marmont, F.; Pogliani, E.; Rossi, G.; Fabris, P.; Porcellini, A.; Musso, M.; Bertoncelli, C.; Sancetta, R.; Di Bona, E.; Intermesoli, T.; Oldani, E.; Rambaldi, A.; Terruzzi, E.; Borlenghi, E.; Crescimanno, A.; Minotto, C.; Chisesi, T.; Coser, P.; Gallo, E.; Barbui, T. 2004: AML in older adults Prognostic improvement by cytogenetic risk group using a risk-adapted, HD-ara-C based multi-cycle program with G-CSF/stem cell support. Annals of Hematology 83(Suppl 1): S13
Buechner, T.; Hiddemann, W.; Woermann, B.; Loeffler, H.; Gassmann, W.; Haferlach, T.; Fonatsch, C.; Haase, D.; Schoch, C.; Hossfeld, D.; Lengfelder, E.; Maschmeyer, G.; Luydwig, W.D.; Sauerland, M.C.; Heinecke, A. 1999: AML in older adults requires intensive rather than attenuated chemotherapy. Annals of Hematology 78(Suppl 2): S17
Lowenberg, B. 2004: AML in older patients Current approach of HOVON-SAKK Cooperative Group. Annals of Hematology 83(Suppl 1): S106
Willman, C.L. 1999: AML in the elderly and secondary AML Biology, prognostic factors, and genetic predisposition. Annals of Hematology 78(Suppl 2): S15
Niederwieser, D.; Hegenbart, U.; Becker, C.; Krahl, R.; Poenisch, W.; Uharek, L.; Al Ali, H.; Moosmann, P.; Gentilini, C.; Wedding, U.; Fiedler, F.; Pasold, R.; Freund, M. 2004: AML studies of the East German Study group - OSHO. Annals of Hematology 83(Suppl 1): S102
Schoch, C.; Kern, W.; Kohlmann, A.; Dugas, M.; Schnittger, S.; Hiddemann, W.; Haferlach, T. 2002: AML with Complex Aberrant Karyotype Can Be Distinguished from All Other AML Subtypes by Gene Expression Profiles and Are Characterized by Higher Expression of Genes Involved in DNA Repair. Blood 100(11): Abstract No. 1204
Schoch, C.; Kern, W.; Schnittger, S.; Kohlmann, A.; Dugas, M.; Hiddemann, W.; Haferlach, T. 2003: AML with complex aberrant karyotype is a distinct entity Evidence provided by chromosome banding analysis, 24-color-FISH, comparative genomic hybridization, gene expression profiling and clinical outcome. Blood 102(11): 375a
Schnittger, S.; Kohlmann, A.; Schoch, C.; Dugas, M.; Kern, W.; Hiddemann, W.; Haferlach, T. 2003: AML with inv /t reveal a specific gene expression signature and dysregulation of many genes involved in megakaryopoiesis and platelet development. Blood 102(11): 215a
Schoch, C.; Haferlach, T.; Schnittger, S.; Kern, W.; Dugas, M.; Hiddemann, W. 2001: AML with recurring chromosome abnormalities as defined in the new WHO-classification Incidence of subgroups, additional genetic abnormalities, FAB subtype and age distribution in an unselected series of 1897 cytogenetically and moleculargenetically analysed AML. Blood 98(11 Part 1): 457a-458a
Choi, S.J.; Oba, T.; Callander, N.S.; Jelinek, D.; Roodman, G.D. 2002: AML-1B down-regulates macrophage inflammatory protein-1alpha expression in multiple myeloma cells. Journal of Bone and Mineral Research 17(Suppl 1): S184-S185
Creutzig, U.; Ritter, J.; Zimmermann, M. 1999: AML-BFM 93 Risk-adapted therapy and randomization in children with AML Preliminary results. Annals of Hematology 78(Suppl 2): S12
Hacihanefioglu, S.; Cirakoglu, A.; Deviren, A.; Kuru, D.; Ongoren, S.; Baslar, Z.; Aktuglu, G. 2001: AML-M3 case report with variant t. Annales de Genetique 44(Suppl 1): s109
Baesecke, J.; Podleschny, M.; Clemens, R.; Schnittger, S.; Truemper, L.; Griesinger, F. 2003: AML-associated genetic aberrations in cord blood-MLL partial tandem duplications, are detectable in stem cells of healthy newborn. Blood 102(11): 844a
De Bont, Eveline S.; Vellenga, Edo; Molema, Grietje; De Leij, Lou H.; Kamps, Willem A. 1999: AML-derived IL-8 production supports angiogenesis. Blood 94(10 Suppl 1 Pt 2): 218b-219b
Niemeyer, C.M.; Duffner, U.; Bender Goetze, C.; Ebell, W.; Hasle, H.; Klingebiehl, T.; Kremens, B.; Nuernberger, W.; Vossen, J.; Zecca, M.; Zintl, F.; Locatelli, F. 2003: AML-type intensive chemotherapy prior to stem cell transplantation does not improve survival in children and adolescents with primary myelodysplastic syndromes. Leukemia Research 27(Suppl 1): S97-S98
Yamaguchi, Y.; Kurokawa, M.; Imai, Y.; Izutsu, K.; Asai, T.; Ichikawa, M.; Yamamoto, G.; Nitta, E.; Yamagata, T.; Sasaki, K.; Mitani, K.; Ogawa, S.; Chiba, S.; Hirai, H. 2004: AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. Journal of Biological Chemistry 279(15): 15630-15638
Ichikawa, M.; Asai, T.; Saito, T.; Seo, S.; Yamamoto, G.; Yamagata, T.; Yamazaki, I.; Kurokawa, M.; Mitani, K.; Hirai, H. 2002: AML1 Is Required for Megakaryocytic Maturation in Adult Hematopoiesis. Blood 100(11): Abstract No. 488
Licht, J.D. 2001: AML1 and the AML1-ETO fusion protein in the pathogenesis of t AML. Oncogene 20(40): 5660-5679, 10 September
Libermann, T.A.; Pan, Z.; Akbarali, Y.; Hetherington, C.J.; Boltax, J.; Yergeau, D.A.; Zhang, D.E. 1999: AML1 cooperates with B cell-specific activating protein in activation of the B cell-specific BLK gene promoter. Journal of Biological Chemistry 274(35): 24671-24676
Barton, K.; Nucifora, G. 2000: AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia. Bioessays: News and Reviews in Molecular Cellular and Developmental Biology 22(3): 214-218
Follows, G.A.; Tagoh, H.; Lefevre, P.; Morgan, G.J.; Bonifer, C. 2003: AML1-ETO acts as a sequence specific transcriptional repressor in vivo by altering the chromatin structure of target genes. British Journal of Haematology 121(Suppl 1): 10
Martinelli, G.; Buonamici, S.; Ottaviani, E.; Giannini, B.; Testoni, N.; Visani, G.; Bonifazi, F.; Terragna, C.; Amabile, M.; Piccaluga, P.P.; Isidori, A.; Malagola, M. 2003: AML1-ETO transcript expression patterns in acute myeloid leukemia patients with t in complete haematological remission. Blood 102(11): 246b
Maki, K.; Yamagata, T.; Asai, T.; Ichikawa, M.; Hirai, H.; Mitani, K. 2003: AML1-Evi-1 knock-in mice show more dysplastic fetal hematopoiesis than AML1-ETO knock-in mice. Blood 102(11): 844a
Wang, Y.; Wang, L.; Lu, S.Y.; Kong, H.; Yuan, W.T.; Jing, Y.E.; Lu, Z.Y.; Chen, S.J.; Chen, Z.; Wang, Z.Y.; Wang, Z.G. 2002: AML1-MTG16 Expression Is Directly Involved in the Development of Acute Myeloid Leukemia. Blood 100(11): Abstract No. 2106
Salomon Nguyen, F.; Coniat, M.B. Le; Pochitaloff, M.L.; Mozziconacci, J.; Berger, R.; Bernard, O.A. 2000: AML1-MTG16 fusion gene in therapy-related acute leukemia with t Two new cases. Leukemia 14(9): 1704-1705
Downing, J.R. 2001: AML1/CBFbeta transcription complex: its role in normal hematopoiesis and leukemia. Leukemia 15(4): 664-665
Basecke, J.; Schwieger, M.; Schiedlmeier, B.; Griesinger, F.; Baum, C.; Wulf, G.; Trumper, L.; Stocking, C. 2002: AML1/ETO Prolongs Survival of Hematopoietic Progenitors but Does Not Abrogate Their Differentiation in NOD/SCID Mice. Blood 100(11): Abstract No. 2119
Liu, S.; Shen, T.; Rush, L.J.; Becknel, B.; Klisovic, M.I.; Whitman, S.P.; Vukosavljevic, T.; Byrd, J.C.; Plass, C.; Marcucci, G. 2003: AML1/ETO associates with DNA methyltransferase 1 in inducing transcriptional repression of the AML1-target gene interleukin-3. Blood 102(11): 218a
Nagel, S.; Krauter, J.; Heidenreich, O.; Nordheim, A.; Ganser, A.; Heil, G. 2001: AML1/ETO mediates repression of CD11c expression in HL60 cells via histone deacetylation. Proceedings of the American Association for Cancer Research 42: 60
Wheeler, J.C.; Wu, Y.; Zelazny, E.T.; Perkins, A.S. 2001: AML1/MDS/Evi-1 cooperation with Bcr-abl in a murine model for CML blast crisis. Blood 98(11 Part 1): 468a-469a
L.S.arza, R.; Sambani, C.; Crescenzi, B.; Matteucci, C.; Martelli, M.F.; Mecucci, C. 2001: AML1/MTG16 fusion gene from a t translocation in treatment induced leukemia after breast cancer Addendum. Haematologica 86(3): 317
Aoki, K.; Shimoda, K.; Matsuda, T.; Numata, A.; Kamezaki, K.; Takase, K.; Haro, T.; Miyamoto, T.; Nagafuji, K.; Gondo, H.; Harada, M. 2002: AML1/MTG8 Leukemic Protein Induces Activation of STAT3. Blood 100(11): Abstract No. 4344
Osato, M.; Yokomizo, T.; Ogawa, M.; Yoshida, H.; Nishikawa, S.I.; Satake, M.; Noda, T.; Ito, Y. 1999: AML1/PEBP2alphaB is essential for the transition from hematogenic endothelial cells to definitive hematopoietic cells. Blood 94(10 Suppl 1 Pt 1): 466a-467a
Bernardin, F.; Collector, M.I.; Friedman, A.D. 2002: AML1/RUNX1 Levels Increase during the Late G1/Early S Cell Cycle Phases and Stimulate S Phase Entry. Blood 100(11): Abstract No. 2085
Bernardin, F.; Collector, M.; Friedman, A.D. 2003: AML1/RUNX1 protein levels increase during the late G1/early S cell cycle phases. Blood 102(11): 847a
Dupret, C.; Asnafi, V.; Libura, M.; Millien, C.; Delabesse, E.; Valensi, F.; Beldjord, K.; Macintyre, E. 2003: AMLs with MLL translocation can be separated into those with T and B lymphoid potential on the basis of their TCR and IgH genetic profiles. Blood 102(11): 21a
Hourdin,F.; Musat,I.; Guichard,F.; Ruti,P.M.; Favot,F.; Filiberti,M.A.; Pham,M.; Grandpeix,J.Y.; Polcher,J.; Marquet,P.; Boone,A.; Lafore,J.P.; Redelsperger,J.L.; Dell'Aquila,A.; Doval,T.L.; Traore,A.K.; Gallee,H. 2010: AMMA-model intercomparison project. Bulletin Of The American Meteorological Society: 1, 95-104
Clark, K.L.; Merkel, L.; Zannikos, P.; Kelley, M.F.; Boutouyrie, B.; Perrone, M.H. 2000: AMP 579, a novel adenosine agonist for the treatment of acute myocardial infarction. Cardiovascular Drug Reviews 18(3): 183-210
Hattori,N.; Nomoto,H.; Fukumitsu,H.; Mishima,S.; Furukawa,S. 2010: AMP N1-oxide, a unique compound of royal jelly, induces neurite outgrowth from PC12 cells via signaling by protein kinase A independent of that by mitogen-activated protein kinase. Evidence Based Complementary And Alternative Medicine: 1, 63-68
Kemp, B.E.; Stapleton, D.I.; Mitchelhill, K.I.; Witters, L.A. 2000: AMP activated protein kinase. Official Gazette of the United States Patent and Trademark Office Patents 1238(4)
Culmsee, C.; Monnig, J.; Kemp, B.E.; Mattson, M.P. 2000: AMP activated protein kinase protects hippocampal neurons against metabolic, excitotoxic and oxidative insults. European Journal of Neuroscience 12(Suppl 11): 231
Bjelakovic, G.; Nagorni, A.; Bjelakovic, M. 2002: AMP deaminase activity and urate levels in liver cirrhosis. Journal of Hepatology 36(Suppl 1): 46
Bjelakovic, G.B.; Benedeto Stojanov, D.; Bjelakovic, M.; Bjelakovic, G. 2000: AMP deaminase activity and urate levels in sera and ascitic fluid of cirrhotic patients as biochemical markers of tissue hypoxia. Journal of Hepatology 32(Suppl 2): 153
Zarzeczny, R.; Terjung, R.L. 1999: AMP deaminase activity in muscle during mild contraction conditions following activation of AMP-activated protein kinase. Medicine and Science in Sports and Exercise 31(5 Suppl): S278
Ching, L.L.; Williams, A.J.; Sitsapesan, R. 1999: AMP is an agonist with low efficacy at the ATP sites on the sheep cardiac ryanodine receptor. Biophysical Journal 76(1 Part 2): A376
Murphy, R.T.; Mogensen, J.; Bahl, A.; Kobu, T.; Holton, J.; Elliott, P.M.; Mcgarry, K.; Mckenna, W.J. 2004: AMP kinase disease in hypertrophic cardiomyopathy Evidence for a multisystem storage disorder. Journal of the American College of Cardiology 43(5 Suppl A): 166A
Rubin, L.J.; Jones, A.W.; Magliola, L.; Price, E.M. 2001: AMP kinase in vascular smooth muscle. FASEB Journal 15(4): A457
Nagata, D.; Walsh, K. 2002: AMP kinase inhibits endothelial cell apoptosis through activation of the PI3K/Atk axis. Circulation 106(19): II304
Holmes, B.; Lang, D.; Mu, J.; Birnbaum, M.; Dohm, G.L.nis 2003: AMP kinase is not a major regulator of GLUT4 gene expression in response to exercise. Diabetes 52(Suppl 1): A12
Sorbera, L.A.; Martin, L.; Leeson, P.A.; Castaner, J. 2000: AMP-579 Treatment of acute myocardial infarction adenosine A1/A2A agonist RPR-100579. Drugs of the Future 25(9): 900-906
Palnitkar, S.S.; Herman, K.; Parness, J. 1999: AMP-PCP enhances dantrolene binding to skeletal muscle sarcoplasmic reticulum. Biophysical Journal 76(1 Part 2): A471
Fleming, I.; Schulz, C.; Kempter, I.; Fichtlscherer, B.; Fisslthaler, B.; Busse, R. 2000: AMP-activated kinase , Akt and Hsp90 regulate the insulin-induced activation of the nitric oxide synthase in human platelets. Nitric Oxide 4(3): 180
Hallows, K.R.; Grieser, H.J.; Bruns, J.R.; Carattino, M.D.; Kleyman, T.R.; Johnson, J.P.; Edinger, R.S. 2003: AMP-activated kinase modulates epithelial Na+ channel activity in oocytes and polarized mouse CCD cells. Journal of the American Society of Nephrology 14(Abstracts Issue): 81A
Hardie, D.Grahame 2001: AMP-activated protein kinase The key sensor of cellular energy charge. Journal of Molecular and Cellular Cardiology 33(6): A146
Yagihashi, N.; Cacicedo, J.; Tsao, T.S.; Lodish, H.; Ruderman, N.; Ido, Y. 2003: AMP-activated protein kinase activator, AICAR and adiponectin inhibit vascular endothelial growth factor induced vascular cell adhesion molecule -1 expression in human aortic endothelial cells. Diabetes 52(Suppl 1): A182
Saranchuk, R.; Altarejos, J.; Lopaschuk, G.D.; Gallo, M.E.; Putman, C.T. 2002: AMP-activated protein kinase activity is greatest in muscles composed of fast-twitch type-IId/x and -IIb fibers. FASEB Journal 16(5): A760
Hemingway, C.J.; Munday, M.R. 1999: AMP-activated protein kinase in rat brain. Journal of Pharmacy and Pharmacology 51(Suppl ): 170
Hallows, K.R.; Mccane, J.E.; Ragburam, V.; Foskett, J.K.vin 2002: AMP-activated protein kinase inhibits CFTR activity by effects on channel gating. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 22A
Graham, M.L.; Setola, V.; Massillon, D. 2001: AMP-activated protein kinase mimics insulins repression of glucose-stimulation of glucose-6-phosphatase gene expression. Diabetes 50(Suppl 2): A287
Um, J.-H.; Park, S.-J.; Kang, H.; Yang, S.; Foretz, M.; McBurney, M.W.; Kim, M.K.; Viollet, B.; Chung, J.H. 2010: AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59(3): 554-563
Zhou, G.; Li, Y.; Chen, Y.; Shen, X.; Doebber, T.; Moller, D.E. 2001: AMP-kinase mediates metabolic effects of metformin. Diabetes 50(Suppl 2): A274
Shah, A.G.; Ren, H.; Musch, M.W.; Walsh Reitz, M.M.; Hart, J.A.; Hogan, N.; Martin, T.E.; Toback, F.G.; Chang, E.B. 2001: AMP18, a novel, cytoprotective, wound-healing, antral mucosal peptide Distribution and potential role in the development of NSAID-induced gastric injury. Gastroenterology 120(5 Suppl 1): A 147
Auberson, Y.P. 2000: AMP397A Novel, broad-spectrum anticonvulsant with potential benefit for therapy-resistant epileptic patients. Abstracts of Papers American Chemical Society 219(1-2): MEDI 14
Xu, Z.; Cohen, M.V.; Heusch, G.; Downey, J.M. 2000: AMP579 at reperfusion limits infarct size in crystalloid-perfused rabbit hearts. Circulation 102(18): 2; 272
Nakamura, M.; Zhao, Z.Q.; Clark, K.L.; Guyton, R.A.; Vinten Johansen, J. 1999: AMP579, a new adenosine analog, inhibits neutrophil O2- generation, degranulation, adherence, and neutrophil-induced injury to coronary vascular endothelium by A2A receptor mechanism. Circulation 100(18): 1; 832
Baxter, G.F.; Ebrahim, Z.; Yelton, D.M. 2000: AMP579, an A1/A2A agonist, limits infarct size at reperfusion via a p42/p44 MAPK-dependent pathway. Circulation 102(18): 2; 212
Baxter, G.F.; Ebrahim, Z.; Yellon, D.M. 2001: AMP579, an adenosine A1 and A2A receptor agonist, attenuates lethal reperfusion injury in rat heart via the P42/P44 MAPK pathway. British Journal of Pharmacology 133(Proceedings Suppl): 7P
Baxter, G.F.; Kis, A.; Yellon, D.M. 2001: AMP579, an adenosine A1 and A2A receptor agonist, limits infarct size in rabbit heart in vivo when given at reperfusion Role of A2A receptor activation. British Journal of Pharmacology 133(Proceedings Suppl): 8P
Desmond, N.L.; Weinberg, R.J. 1999: AMPA and NMDA receptor protein at perforated and nonperforated spine synapses in hippocampal CA1. Society for Neuroscience Abstracts 25(1-2): 1485
Zhou, F.M.; Margolis, J.; Aroniadou Anderjaska, V.; Ennis, M.; Margolis, F.; Borrelli, E.; Shipley, M. 1999: AMPA and NMDA receptor-mediated synaptic transmission between olfactory nerve and juxtaglomerular cells and its presynaptic inhibition by dopamine D2 receptors in mice. Society for Neuroscience Abstracts 25(1-2): 1472
Nusser, Z. 2000: AMPA and NMDA receptors: similarities and differences in their synaptic distribution. Current Opinion in Neurobiology 10(3): 337-341
Hennou, S.; Diabira, D.; Louis, N.C.evassus Au; Ben Ari, Y.; Simon, H.; Gozlan, H. 1999: AMPA and NMDA receptors are functional before birth in the CA1 area of the rat intact hippocampus. Society for Neuroscience Abstracts 25(1-2): 1789
Dube, G.R.; Liu, G. 1999: AMPA and NMDA receptors display similar affinity during rapid synaptic-like glutamate applications. Society for Neuroscience Abstracts 25(1-2): 992
Smith, T.; Groom, A.; Turski, L. 1999: AMPA antagonists ameliorate experimental autoimmune encephalomyelitis. Society for Neuroscience Abstracts 25(1-2): 25
Morales-Alcelay, S.; Rubio, L.; Martinez, A. 2003: AMPA glutamate receptors and neuropathic pain. Mini Reviews in Medicinal Chemistry 3(7): 757-763
Brooks, J.W.; Rice, A.S.C.; Thompson, S.W.N.; Malcangio, M. 2002: AMPA inhibits electrically evoked calcitonin gene-related peptide release from the rat dorsal horn Reversal by cannabinoid antagonist SR141716A. British Journal of Pharmacology 136(Proceedings Suppl): 16P
Kawai, F.; Sterling, P. 1999: AMPA receptor activates a G protein that suppresses a cGMP-gated current in retinal ganglion cells. IOVS Investigative Ophthalmology and Visual Science 40(4): S816
Nikam, S.S.; Kornberg, B.E. 2001: AMPA receptor antagonists. Current Medicinal Chemistry 8(2): 155-170
Rutkauskaite, J.; Wagner, A.; Liljequist, S. 1999: AMPA receptor antagonists reduce ischemic brain damage identified by the novel, neuron-specific, fluorochrome Fluoro-Jade. Society for Neuroscience Abstracts 25(1-2): 577
Noga, J.T.; Hyde, T.M.; Bachus, S.E.; Herman, M.M.; Kleinman, J.E. 2001: AMPA receptor binding in the dorsolateral prefrontal cortex of schizophrenics and controls. Schizophrenia Research 48(2-3): 361-363
Monyer, H.; Fuchs, E.; Meyer, A.; Traub, R.; Doheny, H.; Faulkner, H.J.; Whittington, M.A. 2000: AMPA receptor diversity and regulation thereof in identified neurons. European Journal of Neuroscience 12(Suppl 11): 517
Osten, P.; Ziff, E.B. 1999: AMPA receptor forms a biochemically functional complex with NSF and alpha- and beta-SNAPs. Annals of the new York Academy of Sciences 868: 558-560
Treinies, I.; Sewing, S.; Raap, A.; Delaunois, A.; Depelchin, O.; Holst, J.J.; Gromada, J.; Mest, H.J.; Sher, E. 2003: AMPA receptor isoforms 2 and 3 mediate the stimulatory action of LY451646 on insulin and glucagon secretion in rats. Diabetologia 46(Suppl 2): A166
Strømgaard, K.; Mellor, I. 2004: AMPA receptor ligands: synthetic and pharmacological studies of polyamines and polyamine toxins. Medicinal Research Reviews 24(5): 589-620
Lapierre, L.; Valastro, B.; Gagne, J.; Ghribi, O.; Massicotte, G. 1999: AMPA receptor modulation by calcium in mouse brain sections Bidirectional control in the cortex and striatum formations. Society for Neuroscience Abstracts 25(1-2): 1737
Lynch, G. 2004: AMPA receptor modulators as cognitive enhancers. Current Opinion in Pharmacology 4(1): 4-11
Zarrinmayeh, H.; Zimmerman, D.M.; Ornstein, P.L.; Arnold, M.B.; Xi, X.L.; Skolnick, P. 2001: AMPA receptor potentiators as potentially novel antidepressants. Abstracts of Papers American Chemical Society 222(1-2): MEDI303
O'Neill, M.J.; Bleakman, D.; Zimmerman, D.M.; Nisenbaum, E.S. 2004: AMPA receptor potentiators for the treatment of CNS disorders. Current Drug Targets. Cns and Neurological Disorders 3(3): 181-194
Cornish, J.L.; Sun, A.B.; Kalivas, P.W. 1999: AMPA receptor stimulation in the nucleus accumbens reinstates cocaine-seeking behavior through a dopamine-independent mechanism. Society for Neuroscience Abstracts 25(1-2): 814
Lin, L.H.; Talman, W.T. 2000: AMPA receptor subunit GluR1 and neuronal nitric oxide synthase are colocalized in the nucleus tractus solitarii. FASEB Journal 14(4): A628
Carr, K.D.; Chau, L.S.; Cabeza de Vaca, S.; Gustafson, K.; Stouffer, M.; Tukey, D.S.; Restituito, S.; Ziff, E.B. 2010: AMPA receptor subunit GluR1 downstream of D-1 dopamine receptor stimulation in nucleus accumbens shell mediates increased drug reward magnitude in food-restricted rats. Neuroscience 165(4): 1074-1086
Fragioudaki, K.E.; Mitsacos, A.; Giompres, P.; Smith, A.; Triarhou, L.C.; Kouvelas, E.D. 2000: AMPA receptor subunit RNA transcripts in the cerebellum of normal and Purkinje cell degeneration mutant mice and in cerebellar grafts. European Journal of Neuroscience 12(Suppl 11): 40
Follett, P.L.; Talos, D.M.; Volpe, J.J.; Jensen, F.E. 2003: AMPA receptor subunit expression in human white matter during window of susceptibility to periventricular leukomalacia. Annals of Neurology 54(Suppl 7): S103
Kawahara, Y.kio; Kwak, Shin; Sun, Hui; Ito, Kyoko; Hashida, Hideji; Aizawa, Hitoshi; Kanazawa, Ichiro 2003: AMPA receptor subunit expression profile in spinal motoneurons of normal humans and ALS patients. Neuroscience Research Suppl (26): S52
Longone, P.; Spalloni, A.; Paolucci, E.; Prisco, S.; Mercuri, N.B.; Bernardi, G. 1999: AMPA receptor subunits expression in ALS-linked SOD1 mutant G93A. Society for Neuroscience Abstracts 25(1-2): 1834
Li, P.; Kerchner, G.A.; Sala, C.; Wei, F.; Huettner, J.E.; Sheng, M.; Zhuo, M. 1999: AMPA receptor-PDZ interactions and PKC mediate synaptic facilitation in spinal cord dorsal horn neurons. Society for Neuroscience Abstracts 25(1-2): 1238
Kelland, E.E.; Toms, N.J. 2001: AMPA receptor-mediated excitotoxic cell death in rat cultured oligodendrocyte progenitor cells. British Journal of Pharmacology 133(Proceedings Suppl): 139P
Bravo, S.O.; Henley, J.M.; Rodriguez Ithurralde, D. 2003: AMPA receptors are modulated by acetylcholinesterase. Molecular and Cellular Proteomics 2(9): 736
Rosa, M.L.N.M.; Guimaraes, F.S.; Pearson, R.C.A.; Del Bel, E.A. 2000: AMPA receptors flip isoforms mRNA expression are induced in hippocampus and entohinal cortex by stress. European Journal of Neuroscience 12(Suppl 11): 393
Turrigiano, G.G. 2000: AMPA receptors unbound: membrane cycling and synaptic plasticity. Neuron 26(1): 5-8
Beneyto, M.; Meador-Woodruff, J.H. 2003: AMPA- and NMDA-associated postsynaptic protein expression in the human dorsolateral prefrontal cortex. Annals of the new York Academy of Sciences 1003: 352-355
Lamsa, K.; Palva, M.; Kaila, K.; Taira, T. 1999: AMPA-R-mediated EPSCs in CA1 neurons evoked by synchronous gamma frequency bursts of CA3 region in the P0-P2 rat hippocampus. Society for Neuroscience Abstracts 25(1-2): 993
Kamboj, R.; Elliott, C.E.; Nutt, S.L. 2002: AMPA-binding human GLuR3 receptors. Official Gazette of the United States Patent and Trademark Office Patents 1260(1)
Kamboj, R.; Elliott, C.E.; Nutt, S.L. 2000: AMPA-binding human GluR2 receptors. Official Gazette of the United States Patent and Trademark Office Patents 1232(3)
Kamboj, R.; Elliott, C.E.; Nutt, S.L. 2002: AMPA-binding human gluR4 receptor methods. Official Gazette of the United States Patent and Trademark Office Patents 1256(3)
Jacoby, R.A.; Wu, S.M. 2000: AMPA-preferring receptors mediate excitatory inputs to primate ganglion cells. IOVS Investigative Ophthalmology and Visual Science 41(4): S938
Steinhaeuser, C.; Schroeder, W.; Hinterkeuser, S.; Seifert, G. 2001: AMPA-receptor mediated inhibition of inward rectifier K+ channels in immature astrocytes of mouse hippocampus. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R146
Qin, P.; Pourcho, R.G. 1999: AMPA-selective glutamate receptor subunits GluR2 and GluR4 Localization in the cat retina. IOVS Investigative Ophthalmology and Visual Science 40(4): S236
Kil, A.C.; Bar, P.R.; Shaw, P.J. 2000: AMPA-toxicity in cultured spinal cord slices of SOD1 transgenic mice. European Journal of Neuroscience 12(Suppl 11): 230
Aicher, S.A.; Kraus, J.A.; Patel, A.; Sharma, S. 1999: AMPA-type glutamate receptor density is increased in the nuclei of the solitary tract of spontaneously hypertensive rats. Society for Neuroscience Abstracts 25(1-2): 12
Satake, S.; Konishi, S. 2001: AMPA-type glutamate receptor inhibits cerebellar GABA-mediated transmission via G protein-coupled mechanisms. Zoological Science 18: 107
Krampfl, K.; Schlesinger, F.; Zoerner, A.; Dengler, R.; Bufler, J. 2001: AMPA-type glutamate receptors Contribution of posttranslational mRNA editing to kinetic properties. Pfluegers Archiv European Journal of Physiology 441(6 Suppl): R272
Smith, T.C.; Howe, J.R. 1999: AMPA-type glutamate receptors in migrating cerebellar granule cells. Society for Neuroscience Abstracts 25(1-2): 975
Ratte, S.; Collinge, J.; Jefferys, J.G.R. 2003: AMPA/KA receptor independent epileptiform bursts in the hippocampus of a mouse model of variant CJD. British Journal of Pharmacology 139(Proceedings Suppl): 3P
Satake, S.; Konishi, S. 1999: AMPA/kainate receptor-mediated presynaptic modulation at cerebellar GABAergic synapses. Zoological Science 16(Suppl ): 122
Norman, B.; Knutsson, A.; Sylven, C.; Andersson, B. 2002: AMPD1 gene polymorphism in heart failure patients determined by a new assay. FASEB Journal 16(5): A1129
Taubert, G.; Winkler, R.; Senges, J.; Hoffmann, M.; Maerz, W.; Winkelmann, B.R.; Klein, B.; Goek, R. 2001: AMPD1 gene polymorphism presents no differences in coronary artery disease severity and related complications compared to AMPD1 gene wild type in 3258 invasively investigated patients. European Heart Journal 22(Abstract Suppl): 162
Jobin, J.; Allaire, J.; Noel, M.; Leblanc, P.; Maltais, F. 2002: AMPD1 genotype frequency in patients with COPD. Medicine and Science in Sports and Exercise 34(5 Suppl): S179
Horman, S.; Beauloye, C.; Vertommen, D.; Vanoverscheide, J.L.; Hue, L.; Rider, M.H. 2003: AMPK activation during myocardial ischemia inhibits protein synthesis by increasing eukaryotic elongation factor-2 phosphorylation independently of the mTOR pathway. Circulation 108(17): IV296
Rubin, L.J.; Feng, X.; Magliola, L.; Jones, A.W. 2004: AMPK in Vascular Smooth Muscle Activation by Metabolic Challenge. FASEB Journal 18(4-5): Abstract 829
Hue, L. 2001: AMPK participates in the stimulation of heart glycolysis by ischemia. Journal of Molecular and Cellular Cardiology 33(6): A145
Thomson, D.M.; Gordon, S.E. 2004: AMPK phosphorylation during skeletal muscle overload in young and old rats. FASEB Journal 18(4-5): Abstract 237
Nagata, D.; Mogi, M.; Walsh, K. 2002: AMPK signaling in endothelial cells is essential for angiogenesis under hypoxic but not normoxic conditions. Circulation 106(19): II113
Andreelli, F.; Viollet, B.; Vaulont, S. 2003: AMPK, control of insulin secretion and resistance. M-S (Medecine Sciences) 19(5): 541-542
Sheffield Moore, M.; Yeckel, C.; Jiang, J.; Paddon Jones, D.; Wolfe, R.; Urban, R. 2003: AMPKalpha2 activity in response to moderate-intensity aerobic and resistance exercise in younger and older men. Diabetes 52(Suppl 1): A239
Tamatsukuri, S.; Yawata, H.; Sasaki, M.; Murata, T.; Sakakura, Y.; Hirose, T.; Nunes, J.A.; Pai, A.; Takeuchi, M.; Ohtake, K.; Nishioka, K. 2002: Amplinattm Mpx Hbv/Hcv/Hiv-1 System for Nationwide Blood Screening in Japan. Vox Sanguinis 83(Suppl 2): 114
Lorinczy, D.M.; Belagyi, J. 2000: AMPPNP produces global and local conformational changes in myosin. Biophysical Journal 78(1 Part 2): 235A
Vogel, J.S.; Clifford, A.J. 2004: AMS kinetic analysis of slowly cleared compartments implications for nutraceuticals. FASEB Journal 18(4-5): Abstract 405
Montorsi, F.; Carmgnani, G.; Campo, B.; Giammnusso, B.; Salonia, A.; Briganti, A.; Deho, F.; Rigatti, P. 2004: AMS three-piece inflatable implants for erectile dysfunction A long-term multi-institutional study in 300 consecutive patients. Journal of Urology 171(4 Suppl): 237
Stallmach, A.; Marth, T.; Wittig, B.M.; Neurath, M.; Zeitz, M.; Hombach, A.; Abken, H. 2002: AN IL-12 2-IgG-fusion protein ameliorates TNBS-colitis and inhibits human lymphocyte proliferation and IFN-gamma secretion. Gastroenterology 122(4 Suppl 1): A-391
Pasinetti, G.M.; Ho, L.; Pompl, P. 2002: AN1792 vaccination immunotherapy in Alzheimers disease The case of a therapy before its time. Neurobiology of Aging 23(5): 683-684
Stegmüller, J.; Schneider, S.; Hellwig, A.; Garwood, J.; Trotter, J. 2003: AN2, the mouse homologue of NG2, is a surface antigen on glial precursor cells implicated in control of cell migration. Journal of Neurocytology 31(6-7): 497-505
Lavaud, S.; Canivet, E.; Wuillai, A.; Mohajer, M.; Crost, T.; Renaux, J.L.; Chanard, J. 2001: AN69ST dialysis membrane allows reduced standard heparin doses during dialysis. Nephrology Dialysis Transplantation 16(6): A180
Tuaillon, E.; Borg, J.Y.; Levesque, H.; Jouen Beades, F.; Voiment, H.; Koutouzov, S.; Gilbert, D.; Tron, F. 2000: ANA are frequently observed in the primary anti-phospholipid syndrome and have different immunofluorescence staining patterns and antigenic specificities. Journal of Autoimmunity 15(2): A54
Hughes, R.G.; Karim, A.; Harden, E.L.; Bradwell, A.R. 2003: ANA patterns on ethanol-fixed neutrophils. Kidney and Blood Pressure Research 26(4): 271-272
Truchaud, A.; Delaroche, O. 2003: ANAES and GBEA combined requirements: application to POCT. Annales de Biologie Clinique 61(2): 159-163
Yang, J.; Alcorta, D.; Preston, G.; Munger, W.; Phillips, B.; Jennette, C.; Falk, R. 2000: ANCA IgG and F 2 fragments induce changes in leukocyte gene transcription. Clinical and Experimental Immunology 120(Suppl 1): 41
Jancova, E.; Rihova, Z.; Rychlik, I.; Tesar, V. 2003: ANCA Positive renal vasculitis in the Czech Registry of Renal Biopsies in years 1995-2001. Kidney and Blood Pressure Research 26(4): 251
Hewins, P.; Savage, C.O.S. 2003: ANCA and neutrophil biology. Kidney and Blood Pressure Research 26(4): 221-225
Labonia, W.D.; Arias, C. 2001: ANCA associated interstitial nephritis induced by drugs A case report. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 655A
Bernis, C.; Garcia, A.; Alegre, L.; Fernandez, A.; Cirugeda, A.; Sanchez Tomero, J.A.; Selgas, R. 2002: ANCA associated vasculitis with renal presentation Incidence and natural history. Nephrology Dialysis Transplantation 17(Abstracts Suppl 1): 98
Rajp, A.; Tse, W.Y.; Briggs, D.; Drayson, M.; Savage, C.O.; Adu, D. 2001: ANCA binding to monocytes activates complement. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 638A
Selga, D.; Segelmark, M.; Wieslander, J.; Hellmark, T. 2003: ANCA during active vasculitis recognizes the C-terminal part of PR3. Journal of the American Society of Nephrology 14(Abstracts Issue): 634A
Orth, T.; Neurath, M.; Schirmacher, P.; Galle, P.R.; Mayet, W.J. 2000: ANCA in a novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct. Clinical and Experimental Immunology 120(Suppl 1): 45
Orth, T.; Neurath, M.F.; Schirmacher, P.; Galle, P.R.; Mayet, W.J. 1999: ANCA in a rat model of chronic cholangitis. Journal of Hepatology 30(Suppl 1): 72
Locht, H.; Skogh, T.; Wiik, A. 2000: ANCA in reactive arthritis, rheumatoid arthritis and ulcerative colitis. Clinical and Experimental Immunology 120(Suppl 1): 56
Smyth, C.L.; Pusey, C.D.; Haskard, D.O. 2002: ANCA induce leucocyte adhesion to endothelial cells mediated by E-selectin and integrins under conditions of flow. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 170A
Sediva, A.; Jethwa, H.S.; Bartunkova, J.; Falk, R.J.; Jennette, J.C.arles 2000: ANCA mediated inhibition of pseudomonadocidia in children with CF. Clinical and Experimental Immunology 120(Suppl 1): 54
Jancova, E.; Tesar, V.; Bartunkova, J.; Zabka, J.; Rychlik, I.; Merta, M.; Rysava, R.; Chabova, V.; Stejskalova, A. 1999: ANCA positive patients with renal failure - One centre experience. Blood Purification 17(4): 228
Bae, J.; Choi, H.K.; Niles, J.L. 1999: ANCA positive vasculitis presenting as idiopathic pulmonary fibrosis. Arthritis and Rheumatism 42(9 Suppl): S316
Pelclova, D.; Bartunkova, J.; Fenclova, Z.; Lebedova, J.; Hladikova, M.; Janu, P. 2003: ANCA positivity and occupational exposure to asbestos. Kidney and Blood Pressure Research 26(4): 252
Preston, G.A.; Falk, R.J. 2001: ANCA signaling: not just a matter of respiratory burst. Kidney International 59(5): 1981-1982
Tervaert, J.W.C. 2003: ANCA testing in monitoring the activity of the disease. Kidney and Blood Pressure Research 26(4): 226-230
Stone, J.H.; Talor, M.; Stebbing, J.; Rose, N.R.; Hellmann, D.B.; Burek, C.L.nne 1999: ANCA testing in patients suspected of ANCA-associated conditions Immunofluorescence and ELISA techniques in 916 consecutive patients. Arthritis and Rheumatism 42(9 Suppl): S316
Van Der Geld, Y.M.; Simpelaar, A.; Van Der Zee, R.; Terveart, J.W.C.hen; Stegeman, C.A.; Limburg, P.C.; Kallenberg, C.G.M. 2000: ANCA to proteinase 3 in Wegeners granulomatosis Epitope analysis using synthetic peptides. Clinical and Experimental Immunology 120(Suppl 1): 51
Hauer, H.A.; Bajema, I.M.; Van Houwelingen, J.C.; Noel, L.H.; Ferrario, F.; Waldherr, R.; Bruijn, J.A.; Hagen, E.C. 2001: ANCA-associated glomerulonephritis Differences between diagnostic and serologic subgroups. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 729A
Gibson, K.L.; Szuch, C.L.; Thomas, D.B.; Ferris, M.E.; Davis, L.R.; Gipson, D.S. 2001: ANCA-associated glomerulonephritis in children Patient and renal survival. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 101A
Duran, E.; Merkel, P.A.; Sweet, S.; Swan, N.; Babikian, V.L. 2004: ANCA-associated small vessel vasculitis presenting with ischemic optic neuropathy. Neurology 62(1): 152-153
Iking Konert, C.; Scherer, A.; Schneider, M. 2003: ANCA-associated systemic vasculitis with pulmonary manifestation. Zeitschrift fuer Rheumatologie 62(1): 82-83
Haubitz, M.; Groh, A.; Brunkhorst, R. 2000: ANCA-associated vasculitis and Chlamydia pneumoniae infection. Clinical and Experimental Immunology 120(Suppl 1): 49
Watts, R.; Gonzalez Gay, M.; Garcia Porrua, C.; Lane, S.; Bentham, G.; Scott, D. 2000: ANCA-associated vasculitis in two European regions. Clinical and Experimental Immunology 120(Suppl 1): 60
Kettritz, R.; Choi, M.; Butt, W.; Rane, M.; Rolle, S.; Luft, F.C.; Klein, J.B. 2001: ANCA-mediated activation of human neutrophils is controlled by phosphatidylinositol-3-kinase/Akt. Kidney and Blood Pressure Research 24(4-6): 366
Eisenberger, U.; Fakhouri, F.; Mahr, A.; Vanhille, P.; Beaufils, H.; Guillevin, L.; Lesavre, P.; Noel, L. 2003: ANCA-negative pauci-immune renal vasculitis A clinical and histopathological study of 20 cases. Kidney and Blood Pressure Research 26(4): 281
Moosig, F.; Csernok, E.; Kumanovic, G.; Gross, W.L.dwig 1999: ANCA-opsonisation of apoptotic neutrophils leads to release of proinflammatory mediators after ingestion by macrophages. Arthritis and Rheumatism 42(9 Suppl): S192
Jancova, E.; Tesar, V.; Bartunkova, J.; Zabka, J.; Rychlik, I.; Merta, M.; Rysava, R.; Chabova, V.; Stejskalova, A. 2000: ANCA-positive renal vasculitis One centre experience. Nephrology Dialysis Transplantation 15(9): A85
Greenfield, J.R.; McGrath, M.; Kossard, S.; Charlesworth, J.A.; Campbell, L.V. 2002: ANCA-positive vasculitis induced by thioridazine: confirmed by rechallenge. British Journal of Dermatology 147(6): 1265-1267
Nowack, R.; Grab, I.; Flores Suarez, L.F.; Yard, B.; Van Der Woude, F.J. 1999: ANCA-titers, even of IgG subclasses and soluble CD14 do not reflect disease-activity in patients with ANCA-associated vasculitis. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 517A
Mylonaki, Maria; Buckland, Matthew; Longhurst, Hilary; De Silva, Anupama D.; Ballinger, Anne; Rampton, David 2002: ANCA/ASCA profile in the prediction of clinical phenotype in Crohns disease. Gastroenterology 122(4 Suppl 1): A-179
Bhaskaran, M.; Reddy, K.; Kavuru, S.; Kapasi, A.A.; Singh, J.; Singhal, P.C. 2001: ANG II amplifies HIV-1 gp120-induced mesangial cell apoptosis and oxidative stress. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 798A
Ding, G.; Reddy, K.; Bhaskaran, M.; Singhal, P.C. 2000: ANG II promotes visceral glomerular epithelial cell apoptosis via TGF-beta, smad3, Fas/FasL and altered bcl-2/bax ratio. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 419A
Reddy, K.; Ding, G.; Bhaskaran, M.; Kapasi, A.A.; Singhal, P.C. 2000: ANG II-induced proximal tubular cell apoptosis is mediated through TGF-beta, Fas, FasL, and altered ratio of bcl-2/bax. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 463A
Chiu, T.K.; Dickerson, R.E. 2000: ANG crystal structures of B-DNA reveal sequence-specific binding and groove-specific bending of DNA by magnesium and calcium. Journal of Molecular Biology 301(4): 915-945, 25 August
Bauer, J.A.; Morrison, B.; Oates, R.; Lee, P.; Borden, E.; Lindner, D.J. 2003: ANGIOZYME and interferon-alpha2b synergistically inhibit tumor angiogenesis. Proceedings of the American Association for Cancer Research 44: 230
Hortobagyi, G.; Weng, D.; Elias, A.; Rugo, H.; Urba, W.; Margolin, K.; Radka, S.; Aitchison, R.; Parker, V.; Usman, N.; Capra, W.; Wolin, M.; Gilad, G. 2002: ANGIOZYME treatment of stage IV metastatic breast cancer patients Assessment of serum markers of angiogenesis. Breast Cancer Research and Treatment 76(Suppl 1): S97
Kramer, G.W. 2003: ANIML Analytical Information Markup Language for spectroscopy and chromatography data. Abstracts of Papers American Chemical Society 226(1-2): CINF 80
Bottner, S.; Kuhlmann, M.; Horvay, K.; Heinekamp, T.; Strathmann, A.; Droge Laser, W. 2003: ANK1 A regulator of pathogen-induced cell-death. Free Radical Research 37(Suppl 2): 17
William, M.; Garcia, A.; Hamilton, E.; Bundgaard, H.; Rasmussen, H. 2004: ANP activates the sarcolemmal sodium pump via nitric oxide synthase. Biophysical Journal 86(1): 227a
Barber, M.N.; Gaspari, T.A.; Dusting, G.J.; Woods, R.L. 2000: ANP and CNP preserve endothelium-dependent vasodilation, but only CNP prevents neointima formation, in experimental atherosclerosis. Journal of Submicroscopic Cytology and Pathology 32(3): 449
Schmitt, M.; Broadley, A.J.M.; Gunaruwan, P.; Taylor, J.S.W.; Lee, L.; Cockcroft, J.C.; Struthers, A.; Frenneaux, M.P. 2002: ANP but not CNP modifies forearm vascular tone in CHF. European Heart Journal 23(Abstract Suppl): 424
Tsukada, T.; Takei, Y. 2001: ANP decreases plasma Na+ concentration through its inhibitory actions on drinking and intestinal NaCl absorption. Zoological Science 18: 25
Maron, M.B.; Stader, S.M.; Folkesson, H.G. 2003: ANP does not cause the impaired beta-adrenoceptor-stimulated alveolar liquid clearance produced by prolonged isoproterenol infusion. FASEB Journal 17(4-5): Abstract
Lonardo, G.; Cerbai, E.; Giunti, G.; Bonacchi, M.; Casini, S.; Sani, G.; Mugelli, A. 2002: ANP positively modulates the hyperpolarization-activated current A possible link between stretch and arrhythmogenesis?. Circulation 106(19): II257
Foernges, A.C.; Kiemer, A.K.; Gerwig, T.; Gerbes, A.L.; Vollmar, A.M. 2003: ANP preconditioning attenuates RNA-binding activity of Iron-Regulatory Protein-1 during hepatic ischemia-reperfusion independent of HO-1 induction. Naunyn-Schmiedeberg's Archives of Pharmacology 367(Suppl 1): R106
Gerwig, T.; Meissner, H.; Arnholdt, H.; Bilzer, M.; Kiemer, A.K.; Vollmar, A.M.; Gerbes, A.L. 2001: ANP preconditioning protects against hepatic ischemia-reperfusion injury by attenuating necrotic and apoptotic cell death. Hepatology 34(4 Pt 2): 202A
Schmitt, M.; Nightingale, A.K.; Broadley, A.; Taylor, J.; Campbell, R.; Cockcroft, J.; Frenneaux, M.P. 2001: ANP regulates venous capacitance in man. Clinical Science (London) 101(2): 1P
Borges, A.; Sanchez De Villaroel, S.; De Becemberg, I.L.; Alfonzo, M.J.; Gonzalez De Alfonzo, R. 2000: ANP- and CNP-sensitive guanylyl cyclases are present in bovine airway smooth muscle. Biochemical Society Transactions 28(5): A265
Silberbach, M.; Gorenc, T.; Hershberger, R.E.; Steyger, P.S.; Roberts, C.T.Jr 1999: ANPs anti-hypertrophic action requires activation of MEK and ERK and is Raf independent in neonatal rat ventriculocytes. Pediatric Research 45(4 Part 2): 31A
Perronne, C.; Carrat, F.; Banisadr, F.; Morand, P.; Lunel, F.; Rosenthal, E.; Pol, S. 2002: ANRS HC02 - Ribavic A randomized controlled trial of pegylated-interferona-2b plus ribavirin vs interferona-2b plus ribavirin as primary treatment of chronic hepatitis C in HIV co-infected patients. Hepatology 36(4 Part 2): 283A
Schenk, A.; Roecker, C.; Lamb, D.C.; Nienhaus, G.U.rich 2000: ANS binding to apomyoglobin studied by time-gated fluorescence correlation spectroscopy. European Biophysics Journal 29(4-5): 266
Jankovic, N.; Varlaj Knobloch, V.; Pavlovic, D. 2001: ANS dysfunction and blood pressure regulation in CAPD patients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 429A
Dehmel, J.C. 1999: ANSI/HPS N1353 TENORM Standard-Update of development activities. Health Physics 76(6 Suppl): S169
Chavany, C.; Martini, J.F.; Valle, R.P.C.; Jendoubi, M. 2002: ANTIBIOMIXTM Antibody-based target discovery and validation for cancer by matrix protein array. Proceedings of the American Association for Cancer Research 43: 455
Atwell, J.E.; Vinson, C.; Yuspa, S.H. 2001: AO-1 mediates apoptosis and altered epidermal differentiation in keratinocytes from PKCalpha transgenic mice. Proceedings of the American Association for Cancer Research 42: 422
Chojnowski, A.; Coleman, N. 1999: AO/ASIF unreamed femoral nail: a minimally invasive approach to its insertion. Injury 30(3): 226-230
Anonymous 2003: AOHC Session 2301 Current Research in Occupational and Environmental Medicine, Altanta, GA, USA, May 3-8, 2003. Journal of Occupational and Environmental Medicine 45(7): 771-775
Rosenberg, D.W.; Bolt, A.B. 2000: AOM induces K-ras activation in the tumor resistant AKR/J mouse colon. Proceedings of the American Association for Cancer Research 41: 104
Banerjee, S.; Bhattacharyya, N. 2002: AP endonuclease, PARP and XRCC1 proteins interact with a truncated DNA polymerase beta, a DNA repair protein. Environmental and Molecular Mutagenesis 39(Suppl 33): 15
Johansen, C.; Iversen, L.; Ryborg, A.; Kragballe, K. 2000: AP-1 DNA binding activity is significantly reduced in involved psoriatic skin In vitro and in vivo regulation of AP-1 DNA binding activity by 1alpha,25 2D3 and calcipotriol. Journal of Investigative Dermatology 115(3): 534
Luo, F.; Hu, Z.; Zhao, X.; Yin, L.; Ya, C. 2001: AP-1 activated by latent membrane protein 1 is involved in progression of nasopharyngeal carcinoma. Proceedings of the American Association for Cancer Research 42: 769
Eldred, A.K.; Durvasula, R.; Walz, G.; Cantley, L.G. 1999: AP-1 activation during treatment in chronic hemodialysis patients. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 71A
Daury, L.; Rodier, A.; Rochard, P.; Casas, F.; Busson, M.; Gamaleri, F.; Wrutniak Cabello, C.; Cabello, G. 2000: AP-1 activity is a crucial target of triiodothyronine involved in the stimulation of myoblast differentiation induced by the hormone. Endocrine Journal 47(Suppl August): 238
Kagami, S.; Urushihara, M.; Kondo, S.; Kitamura, M.; Koster, K.; Hisayama, T.; Kuroda, Y. 2000: AP-1 activity mediates alpha1beta1 integrin-dependent collagen matrix remodeling by rat mesangial cells. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 531A
Mccabe, J.T.; Burrell, A.S. 1999: AP-1 and CREB protein DNA binding in rat supraoptic and paraventricular nuclei after acute and repeated osmotic stimulation. Society for Neuroscience Abstracts 25(1-2): 1693
Robinson, M.S.; Lui, W.W.Y.; Hirst, J. 2001: AP-1 and GGAs Two adaptors for TGN to endosome trafficking. Biochemical Society Transactions 29(3): A46
Lim, K.; Son, M.Y.; Seo, W.H.; Park, C.; Park, J.I.; Park, S.K.; Hwang, B.D. 2001: AP-1 and NF-kB are related to genistein-dependent induction of vimentin gene in HL-60 cells. European Journal of Cancer 37(Suppl 6): S130
Wang, J.; Khaletskiy, A.; Wong, J.Y.C.; Young, M.R.; Colburn, N.H.; Li, J.J.an 2000: AP-1 and NFKAPPAB are involved in radioresistance generation in human keratinocytes transformed by HPV18 E6/E7 and v-fos genes. Proceedings of the American Association for Cancer Research 41: 707
Kawachi, Y.; Roop, D. 2001: AP-1 and Sp1 cooperatively regulate differentiation-specific expression of the mouse loricrin gene via direct association. Journal of Investigative Dermatology 117(2): 523
Taimor, G.; Schneiders, D.; Best, P.; Piper, H.M. 2003: AP-1 and other transcription factors in apoptotic and hypertrophic cardiomyocytes. European Heart Journal 24(Abstract Suppl): 693
Krishna, N.S.; Edwards, J.; Underwood, M.A.; Grigor, K.M.; Bartlett, J.M.S. 2002: AP-1 as a mediator of androgen refractory prostate cancer. British Journal of Cancer 86(Suppl 1): S92
Chunhua, L.; Shen, Q.; Kim, H.; Denardo, D.; Wu, K.; Brown, P. 2003: AP-1 blockade inhibits breast cancer cell growth by preventing the recruitment of coactivators. Proceedings of the American Association for Cancer Research 44: 464
Shen, Q.; Lu, C.; Liu, Y.M.; Denardo, D.; Kim, H.T.; Brown, P.H. 2003: AP-1 blockade inhibits growth and suppresses G1 cyclin expression in breast cancer cells. Proceedings of the American Association for Cancer Research 44: 634
Liu, Y.; Zhang, Y.; Ludes Meyers, J.; Munoz Medellin, D.; Kim, H.T.; Ge, G.; Schiff, R.; Osborne, C.K.; Brown, P.H. 2001: AP-1 blockade suppresses the in vitro and in vivo growth of MCF-7 breast cancer cells. Proceedings of the American Association for Cancer Research 42: 128
Hafezi, F.; Grimm, C.; Weitzman, J.B.; Wenzel, A.; Yaniv, M.; Reme, C.E. 1999: AP-1 complexes containing JunD are not essential for light-induced photoreceptor degeneration. IOVS Investigative Ophthalmology and Visual Science 40(4): S226
Sadowska, B.; Barrucco, R.; Radhakrishnan, S.; Kim, J.; Khalili, K.; Safak, M. 2002: AP-1 family members, c-Jun and c-Fos, regulate transcription from JC virus promoters in glial cells. Journal of Neurovirology 8(Suppl 1): 107-108
Alfano, M.; Vicenzi, E.; Rizzi, C.; Tambussi, G.; Lazzarin, A.; Poli, G. 2002: AP-1 mediated-CXCL8 expression up-regulates HIV infection and virus replication. Journal of Interferon and Cytokine Research 22(Suppl 1): S-185
Bradbury, C.M.; Wei, S.J.; Locke, J.E.; Spitz, D.R.; Gius, D. 1999: AP-1 overexpression in H2O2-resistant cells contributes to resistance to thermal radiosensitization. Free Radical Biology and Medicine 27(Suppl 1): S59
Hornberg, J.J.; Langerak, P.; Dekker, H.; Lankelma, J. 2003: AP-1 plays a role in cell-cell contact-mediated inhibition of cell growth in NRK fibroblasts. Proceedings of the American Association for Cancer Research 44: 262-263
Dobretsova, A.; Kokorina, N.A.; Wight, P.A. 2001: AP-1 potentiates myelin proteolipid protein gene expression through protein-DNA interactions formed in the antisilencer region of intron 1. Journal of Neurochemistry 78(Suppl 1): 167
Hilfiker Kleiner, D.; Hilfiker, A.; Kaminski, K.; Wollert, K.; Castellazzi, M.; Drexler, H. 2002: AP-1 transcription factor JunD is a negative regulator of cardiomyocyte hypertrophy. Circulation 106(19): II141
Toone, W.M.; Jones, N. 1999: AP-1 transcription factors in yeast. Current Opinion in Genetics and Development 9(1): 55-61
Gerdes, M.J.; Frost, N.A.; Levy, M.R.; Moitra, J.; Glick, A.B.; Vinson, C.; Yuspa, S.H. 2004: AP-1 transcriptional activity determines keratinocyte lineage commitment during tumorigenesis. Journal of Investigative Dermatology 122(3): A22
Carter, A.B.; Tephly, L.A.; Hunninghake, G.W. 2001: AP-1-dependent gene expression in macrophages stimulated by phorbol esters requires an active p38 MAP kinase. FASEB Journal 15(4): A5
Kido, S.; Inoue, D.; Matsumoto, T. 2001: AP-1/interleukin -11 signaling cascades may be involved in PTH-induced bone formation ERK-dependent induction of delta-fosB and IL-11 by hPTH. Journal of Bone and Mineral Research 16(Suppl 1): S175
Proteau, G.A.; Wener, A.; Monge, J.C.rlos 2000: AP-2 activates an element in the 5untranslated region of the endothelin A receptor potentially regulating its developmental expression. Circulation 102(18): 2; 86
Van Laar, E.S.; Bar Eli, M.; Price, J.E. 1999: AP-2 expression reduces the metastatic potential of MDA-MB-231 breast cancer cells. Proceedings of the American Association for Cancer Research 40: 198
Ruiz, M.; Pettaway, C.; Song, R.; Troncoso, P.; Bar Eli, M. 2002: AP-2 transcription factor is a tumor suppressor gene in prostate cancer. Proceedings of the American Association for Cancer Research 43: 139
Ruiz, M.; Pettaway, C.; Troncoso, P.; Bar Eli, M. 2001: AP-2 transcription factor is associated with luminal differentiation in normal prostate epithelium and it is lost in prostate cancer. Proceedings of the American Association for Cancer Research 42: 625
Shaz, B.; Zhao, S.; Tahan, S. 2000: AP-2 transcription factor is upregulated in human in-situ and invasive malignant melanoma. Laboratory Investigation 80(3): 68A
West Mays, J.A.; Sivak, J.M.; Papagiotas, S.S.; Coyle, B.M.; Mohan, R.; Williams, T.; Fini, M.E. 2001: AP-2 transcription factors in the differentiating and regenerating corneal epithelium. IOVS Investigative Ophthalmology and Visual Science 42(4): S477
Coyle, B.M.; Papagiotas, S.S.; Choi, G.; Piatigorsky, J.; West Mays, J.A. 2001: AP-2alpha transcription factor controls cell migration in the developing lens. IOVS Investigative Ophthalmology and Visual Science 42(4): S922
Ahituv, N.; Erven, A.; Fuchs, H.; Balling, R.; De Angelis, M. Hrabe; Steel, K.P.; Avraham, K.B. 2001: AP-2alpha transcription factor mutation demonstrates the power of ENU. American Journal of Human Genetics 69(4 Suppl): 340
Sugita, M. 2003: AP-3-dependent immunity against microbial infection. Cell Structure and Function 28(4): 277
Piao, Z.; Malkhosyan, S. 2000: AP-PCR DNA fingerprinting of breast cancer. Proceedings of the American Association for Cancer Research 41: 277
Lukiw, W.J.; Mukherjee, P.K.; Dixon, D.; Prescott, S.M.; Leblanc, H.J.; Carver, L.A.; Bazan, N.N.G. 1999: AP1 and NF-kappaB levels in Alzheimers disease and age-matched association neocortex Relevance to neuroinflammatory processes and cyclooxygenase-2 transcription. Journal of Neurochemistry 72(Suppl ): S73
Saika, S.; Ohnishi, Y.; Ooshima, A.; Kao, W.W.Y. 2000: AP1 component expression in human ocular surface epithelia and in epithelial dysplasia before and after topical mitomycin C treatment. IOVS Investigative Ophthalmology and Visual Science 41(4): S259
Boord, J.B.; Fazio, S.; Uysal, K.; Babaev, V.R.; Brown, A.M.; Makowski, L.; Maeda, K.; Hotamisligil, G.S.; Linton, M.F. 2000: AP2 fatty acid binding protein expression by macrophages accelerates early atherosclerotic lesion formation in apo-E deficient mice. Circulation 102(18): 2; 230
Pietrzykowski, E. 2002: AP2-5B6 anti-HPV6b E5b. Hybridoma and Hybridomics 21(6): 509
Pietrzykowski, E. 2002: AP2-5G2 anti-HPV6b E7. Hybridoma and Hybridomics 21(6): 508
Senic Matuglia, F.; Goud, B.; Salamero, J. 2000: AP3-betaB A new interacting protein for Rab11 Their putative involvement in melanogenesis. Biology of the Cell 92(2): 172
Arvola, L.; Hassaf, D.; Ytrehus, K. 2001: AP5A and contractile function of guinea pig heart muscle. Journal of Molecular and Cellular Cardiology 33(6): A4
Van Ginneken, E.; Rongen, G.; Smits, P. 2000: AP5A-induced vasodilation is inhibited by theophylline in the human forearm vascular bed. Journal of Hypertension 18(Suppl 4): S215
Ramboyong, R.; Marinas, C.E.; Lim, A.; Flores, D.; Caguioa, E. 2001: APACHE II scores used as predictors of outcome in hypertensive patients with stroke admitted at ICU. European Journal of Neurology 8(Suppl 2): 41
Wang, X. 2002: APAF-1 an activator of caspase-3. Official Gazette of the United States Patent and Trademark Office Patents 1255(2)
Furukawa, Y.suke; Nishimura, Noriko; Kano, Yasuhiko; Nakamura, Mitsuru 2001: APAF-1 is a mediator of E2F-1-induced apoptosis in hematopoietic cells. Blood 98(11 Part 1): 758a-759a
Jada, S.R.; Stanslas, J.; Lajis, N.H.; Saad, S.; Hamzah, A.S.; Mccorroll, A.; Mathews, C.; Stevens, M.F.G. 2003: APAG-1 derivatives as antitumour agents. British Journal of Cancer 88(Suppl 1): S29
Cziepluch, C.; Bashir, T.; Lampel, S.; Lichter, P.; Grund, C.; Rommelaere, J. 2001: APAR-bodies Distinct autonomous parvovirus-induced nuclear structures. Biology of the Cell 93(3-4): 210
Niell, B.L.; Rennert, G.; Tomsho, L.P.; Bonner, J.D.; Gruber, S.B. 2002: APC D1822V and the risk of colorectal cancer. American Journal of Human Genetics 71(4 Suppl): 246
Petersen, G.M.; Hahnloser, D.; Rabe, K.; Snow, K.; Boardman, L.; Lindor, N.M.; Koch, B.; Wang, L.; Thibodeau, S.N. 2001: APC E1317Q variant is not associated with increased colorectal neoplasia risk. American Journal of Human Genetics 69(4 Suppl): 274
Bienz, M. 1999: APC: the plot thickens. Current Opinion in Genetics and Development 9(5): 595-603
Garza, K.M.; Chan, S.; Suri, R.; Schoenberger, S.; Ohashi, P.S. 2000: APC activation through CD40 breaks tolerance and induces autoimmunity. Journal of Investigative Dermatology 114(1): 215
Iwamoto, M.; Maltzman, T.; Ahnen, D.J. 1999: APC and beta-catenin expression in normal and neoplastic colonic mucosa. Gastroenterology 116(4 Part 2): A427
Akiyama, Y.; Nagasaki, H.; Nomizu, T.; Yuasa, Y. 2000: APC and beta-catenin gene mutations in colorectal adenomas from HNPCC patients. Proceedings of the American Association for Cancer Research 41: 595
Iwamoto, M.; Giardiello, F.M.; Boland, C.R.; Romans, K.; Chauhan, D.P.; Ahnen, D.J. 2001: APC and beta-catenin protein expression in adenomas of patients with familial polyposis. Gastroenterology 120(5 Suppl 1): A 294
Maltzman, T.; Iwamoto, M.; Franklin, W.; Stephens, J.; Ahnen, D. 1999: APC and beta-catenin staining in AOM-induced mouse colon tumors. Proceedings of the American Association for Cancer Research 40: 697
Silye, R.; Webersinke, G.; Heuritsch, S. 1999: APC and c-neu in malignant and benign melanocytic lesions. Virchows Archiv 435(3): 314
Bertagnolli, M.M. 1999: APC and instestinal carcinogenesis insights from animal models. Bradlow, H Leon Author, Fishman, Jack Author, Osborne, Michael P Author Annals of the New York Academy of Sciences; Cancer prevention: Novel nutrient and pharmaceutical developments 32-44
Yang, V.W. 2002: APC as a checkpoint gene: the beginning or the end?. Gastroenterology 123(3): 935-939
Gerstein, A.V.; Zhao, G.; Almeida, T.A.; Chess, E.; Papadopoulos, N. 2000: APC beta-catenin pathway mutations in cancers of the prostate. Proceedings of the American Association for Cancer Research 41: 872
Sanchez, M.; Meier, C.; Garcia, M.; Kaye, P. 1999: APC function of granuloma derived macrophages. Immunology 98(Suppl 1): 52
Lee, J.H.; Abraham, S.C.; Nam, J.H.; Choi, C.; Lee, M.C.; Park, C.S.; Juhng, S.W.; Rashid, A.; Hamilton, S.R.; Wu, T.T. 2002: APC gene mutations in gastric adenomas and flat dysplasias protect against progression. Laboratory Investigation 82(1): 135A-136A
Womack, L.; Lee, L.A.; Hylind, L.M.; Giardiello, F.M. 2000: APC germline mutations result in increased c-MYC expression in the flat mucosa of FAP patients. Gastroenterology 118(4 Suppl 2 Pt 1): A43
Louis, T.H.; Reed, B. 2003: APC localization linked to myosin VI movement through interaction with GLUT1CBP. Abstracts of Papers American Chemical Society 225(1-2): CHED 839
Laken, S.; Gruber, S.; Petersen, G.; Kinzler, K.; Vogelstein, B. 1999: APC mutation associated with familial colorectal cancer in ashkenazi jews. Official Gazette of the United States Patent and Trademark Office Patents 1220(2): 1495
Peters, J.A.; Lotze, M.T.; Sproul, L.; Pratt, V.; Rubinstein, W.S. 1999: APC mutation in woman with multiple desmoids A new syndrome or FAP variation?. American Journal of Human Genetics 65(4): A315
Meuller, J.; Engwall, Y.; Bergman, A.; Wahlstrom, J.; Bjork, J.; Nordling, M. 2001: APC mutations in Swedish FAP patients Preliminary results. American Journal of Human Genetics 69(4 Suppl): 252
Kim, J.C.; Roh, S.A.; Yu, C.S.; Kim, K.M.; Yang, S.K.; Kang, K.H.; Beck, N.E.; Bodmer, W.F. 1999: APC mutations in the hamartomatous and hyperplastic polyps of the colon. Proceedings of the American Association for Cancer Research 40: 274
Aust, D.E.; Terdiman, J.P.; Willenbucher, R.F.; Chang, C.G.; Baretton, G.B.; Waldman, F.M.; Loehrs, U. 2000: APC mutations in ulcerative colitis-related and sporadic colorectal cancers. Pathology Research and Practice 196(6): 409
Arnold, C.N.; Goel, A.; Compton, C.; Niedzwiecki, D.; Wasserman, L.; Mayer, R.J.; Bertagnolli, M.M.; Boland, C.R.chard 2002: APC promoter hypermethylation contributes strongly to loss of APC expression in colorectal cancers with allelic loss at 5q A study of CALGB 9865. Gastroenterology 122(4 Suppl 1): A-121
Palacios, J.; Esteller, M.; Matias Guiu, X.; Catasus, L.; Guo, M.; Moreno Bueno, G.; Hardisson, D.; Herman, J.G.; Prat, J. 2002: APC promoter hypermethylation in endometrial carcinomas. Laboratory Investigation 82(1): 205A
Mimori Kiyosue, Y.ko; Tsukita, Shoichiro 2001: APC protein is recruited to the cell cortex through its COOH-terminal PDZ-binding domain. Molecular Biology of the Cell 12(Suppl): 308a-309a
Van Der Neut Kolfschoten, M.; Dirven, R.J.; Tans, G.; Rosing, J.; Vos, H.L.; Bertina, R.M. 2000: APC resistance and mutations in the APC cleavage sites of factor V. Haemostasis 30(Suppl 1): 27-28
Schneider, D.M.; Heilmann, L.; V. Tempelhoff, G.F.; Niemann, F.; Knirsch, K. 1999: APC resistence and ProC Global in mothers and newborn cord blood at delivery. Annals of Hematology 78(Suppl 1): A87
Javid, S.H.; Hunt, D.H.; Moran, A.E.; Mueller, J.D.; Carothers, A.M.; Bertagnolli, M.M. 2003: APC truncation alters cytoskeletal function in the Min/+ mouse model of colorectal cancer. Proceedings of the American Association for Cancer Research 44: 287
Hughes, S.A.; Hunt, D.H.; Moran, A.E.; Mueller, J.D.; Carothers, A.M.; Bertagnolli, M.M. 2002: APC truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis. Gastroenterology 123(1 Suppl): 7
Kapitanovic, S.; Cacev, T.; Radosevic, S.; Spaventi, R.; Pavelic, K. 2002: APC tumor suppressor gene in sporadic colon cancer. European Journal of Cancer 38(Suppl 1): S51
Liu, Z.; Hsu, H.; Xie, J.; Yang, P.; David, C.S.; Xu, X.; Mountz, J.; Zhang, H.G. 2002: APC-AdFasL treatment leads to clonal deletion of CII specific T cells and prevents CII induced arthritis in DQ8 transgene mice. FASEB Journal 16(5): A1045
Daly, C.; Dube, C.; Rollins, B.J. 2004: APC-Derived Monocyte Chemoattractant Protein-1 Provides Costimulatory Activity for CD4 Cells. FASEB Journal 18(4-5): Abstract 336
Grabbe, S.; Varga, G.; Gunzer, M. 2003: APC-T cell interactions during antigen presentation Relevance of beta2 integrins and differences between APC types. Journal of Investigative Dermatology 121(5): 1234
Meuller, J.; Bjork, J.; Engwall, Y.; Gronberg, H.; Holmberg, E.; Nordling, M. 2001: APC-gene mosaicism in sporadic attenuated FAP. European Journal of Human Genetics 9(Suppl 1): P0046
Rockwell, J.K.; Renshaw, M.; Katz, J.; Sambhara, S. 2002: APC/T cell contact kinetics and antigen threshold requirements for influenza nucleoprotein-specific CD8+ T cell clonal expansion. FASEB Journal 16(4): A718
Yamanaka, H.; Kondo, E.; Noguchi, K.; Koyama, K.; Nakagawa, H.; Nakamura, Y. 2000: APCL mRNA expression during mouse development. Neuroscience Research Suppl (24): S130
Ghio, Luciana; Boccola, Salvatore; Edefonti, Alberto; Vrech, Simone; Adami, Daniele; Garavaglia, Rosanna; De Chiara, Benedetta; Paglialonga, Fabio; Ardissino, Gianluigi 2002: APD patients management with the use of a new telecommunication system. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 395A
Kent, T.A.; Edwards, M.; Izumi, T.; Mitra, S.; Perez Polo, J.R.gino 1999: APE/Ref-1 DNA repair enzyme following middle cerebral artery occlusion/reperfusion. Stroke 30(1): 247
Metspalu, A.; Tonisson, N.; Zernant, J.; Lushnikov, A.; Kask, I.; Kurg, A. 2000: APEX chip for p53. European Journal of Human Genetics 8(Suppl 1): 144
Kepp, K.; Remm, M.; Lohmussaar, E.; Gerst Talas, U. 2002: APEX scaling up Optimisation of the high throughput Arrayed Primer Extension based DNA variation analysis for accurate and affordable large-scale projects. European Journal of Human Genetics 10(Suppl 1): 297
Pereira, C.ân.F.; Paridaen, J.T.M.L.; van de Bovenkamp, M.; Middel, J.; Verhoef, J.; Nottet, H.S.L.M. 2003: APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro. Journal of Antimicrobial ChemoTherapy 51(5): 1181-1189
Sugiyama, T.; Asaka, M.; Nakamura, T.; Nakamura, S.; Yonezumi, S.; Seto, M. 2001: API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma. Gastroenterology 120(7): 1884-1885
Sagaert, Xavier; De Wolf Peeters, Christiane; Marynen, Peter; Baens, Matthys 2003: API2-MLT transgenic mice A model for the pathogenesis of MALT lymphomas?. Blood 102(11): 586a
Duncan, S.L. 2000: APIC State-of-the-Art Report: the implications of service animals in health care settings. American Journal of Infection Control 28(2): 170-180
Zabransky, R.J. 2001: APIC defines home health care infection criteria. Clinical Microbiology Newsletter 23(8): 64
Suzuki, A. 2000: APKC-PAR system mediates formation of polarized junctional structures and cell epithelialization. Cell Structure and Function 25(6): 372
Pierangeli, S.S.; Liu, X.; Espinola, R.G.; Harris, E.N. 2002: APL affects protein C activation in vivo. Lupus 11(9): 584
Levine, S.R.; Brey, R.L.; Tilley, B.C.; Thompson, J.L.T.; Sacco, R.L.; Costigan, T.M.; Rhine, C.; Murphy, A.; Levin, B.; Sciacca, R.R.; Triplett, D.A.; Mohr, J.P.; Apass Study Group 2002: APL and Stroke Study. Lupus 11(9): 559
Dawood, F.; Farquharson, R.G.; Quenby, S. 2002: APL and acquired activated protein C resistance Risk factors for fetal loss. Lupus 11(9): 562
Colorio, C.; Forastiero, R.; Martinuzzo, M.; Macchia, A.; Pombo, G.; Puente, D.; Rossi, A.; Carreras, L. 2002: APL and heparin induced thrombocytopenia type II in chronic thromboembolic pulmonary hypertension. Lupus 11(9): 593
Rai, R. 2002: APL and pregnancy loss Beyond thrombosis. Lupus 11(9): 563
Mcintyre, J.A.; Wagenknecht, D.R. 2002: APL and renal transplantation A risk assessment. Lupus 11(9): 546
Brey, R.L.; Levine, S.R. 2002: APL and the brain Treatment. Lupus 11(9): 559
Victoria, E.J.; Marquis, D.M.; Jones, D.S.; Yu, L. 2002: APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies. Official Gazette of the United States Patent and Trademark Office Patents 1259(4)
Toubi, E.; Kessel, A.; Hallas, K.; Zuckerman, E. 2002: APL in patients suffering from autoimmune hepatitis and primary biliary cirrhosis. Lupus 11(9): 623
Pierangeli, S.S.; Blank, M.; Espinola, R.G.; Shoenfeld, Y.; Harris, E.N.; Gharavi, A. 2002: APL induced by immunization with the phospholipid-binding site of B2glycoprotein I recognize conformational epitopes on a bacterial peptide. Lupus 11(9): 610
Mak, I.Y.H.; Rai, R.; Brosens, J.J.; Christian, M.; Hills, F.A.; Chamley, L.; Regan, L.; White, J.O. 2002: APL inhibition of human endometrial stromal cell differentiation in vitro. Lupus 11(9): 563
Raschi, E.; Testoni, C.; Corsini, E.; Khamashta, M.A.; Tincani, A.; Balestrieri, G.; Salmaggi, A.; Hess, D.; Meroni, P.L. 2000: APL reactivity with human brain microvascular endothelial cells. Journal of Autoimmunity 15(2): A26
Mandal, A.; Klotz, K.; Wolkowicz, M.J.; Shetty, J.; Jayes, F.L.; Flickinger, C.J.; Herr, J.C. 2000: APL17 and APLX Two novel human acrosomal pseudo-lysozymes. Molecular Biology of the Cell 11(Suppl): 520a-521a
Pierangeli, S.S.; Hall, J.L.; Espinola, R.G.; Ferrara, D.E.; Roye Green, K.; Harris, E.N. 2002: APLs activate nuclear factor kappa B on endothelial cells. Lupus 11(9): 589
Kim, H.; Conti Kelly, A.M.; Greco, T. 2002: APLs and recurrent coronary events after angioplasty. Lupus 11(9): 567
Bougueleret, L.; Bihain, B.; Denison, B.; Yen Potin, F. 2003: APM1 biallelic markers and uses thereof. Official Gazette of the United States Patent and Trademark Office Patents 1271(4)
Kinyoun, J.L. 2000: APMPPE associated with Wegener's granulomatosis. Retina 20(4): 419-420
Lanza Jacoby, S.; Miller, S. 1999: APO E-/- mice have increased mortality after endotoxin challenge. FASEB Journal 13(5 Part 2): A840
Javadi, E.; Doosti, M.; Rashtchizadeh, N.; Mohaghaghi, A.; Mahmoodi, M. 2001: APO isoforms and LP concentration in predict risk for coronary artery disease, a study in men 55 years of age. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S296
Buzello, M.; Schumm, K.; Toernig, J.; Faulhaber, J.; Ehmke, H.; Ritz, E.; Amann, K. 2002: APO knockout mice A new model to study the pathogenesis of cardiovascular changes in chronic renal failure. Pathology Research and Practice 198(3): 145-146
Trieb, K.; Cetin, E. 2003: APO-1 and Caspase-8 are distinct expressed in the human growth plate. Calcified Tissue International 72(4): 434
Valle, M.; Gascon, F.; Martos, R.; Ruz, F.J.; Rios, R.; Canete, R. 2001: APO-AI decrease and triglycerides increase serum levels in hyperinsulinemic obese children. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S247
Goldstein, L.B.; Vitek, M.P.; Dawson, H.; Bullman, S. 1999: APO-E genotype does not affect motor recovery after motor cortex injury in the mouse. Society for Neuroscience Abstracts 25(1-2): 822
Bishop, K.N.; Holmes, R.K.; Sheehy, A.M.; Malim, M.H. 2004: APOBEC-mediated editing of viral RNA. Science 305(5684): 645
Corbo, R.M.; Gambina, G.; Ruggeri, M.; Ferrari, G.; Scacchi, R. 1999: APOE -491 A/T polymorphism Lack of association with Alzheimers disease and relationships with apoE plasma levels. European Journal of Human Genetics 7(Suppl 1): 141
Martin, G.M. 1999: APOE alleles and lipophylic pathogens. Neurobiology of Aging 20(4): 441-443
Lovestone, S. 2000: APOE and Alzheimers disease Is tau the link?. Biochemical Society Transactions 28(1): A16
Singh, P.; Singh, M.; Mastana, S.S. 2003: APOE distribution in world populations with new data from the Indian and the British populations. American Journal of Human Genetics 73(5): 381
Singh, P.P.; Singh, M.; Gill, P.S.; Mastana, S.S. 2003: APOE distribution in world populations with new data from the Indian sub-continent and the British populations. American Journal of Physical Anthropology Suppl (36): 192
Diaz Arrastia, R.; Fair, S.; Gong, Y.; Agostini, M.A. 2002: APOE epsilon4 allele increases risk of late posttraumatic seizures. Epilepsia 43(Suppl 7): 275
Aerssens, J.; Raeymaekers, P.; Lilienfeld, S.; Parys, W. 1999: APOE genotype and response to galantamine treatment in Alzheimers disease. American Journal of Human Genetics 65(4): A195
Evans, R.M.; Hui, S.; Murrell, J.; Gao, S.; Lane, K.A.; Hall, K.S.; Hendrie, H.C. 2001: APOE genotype and risk for AD in a population-based study of African Americans Prevalence and incidence data. Neurology 56(8 Suppl 3): A112-A113
Grocott, H.P.; Laskowitz, D.T.; El Moalem, H.; Bainbridge, D.; Butler, A.M.; Newman, M.F. 2001: APOE genotype differentially influences the pro and anti-inflammatory response to cardiopulmonary bypass. Anesthesia and Analgesia 92(4 Suppl): SCA18
Frank, A.; Díez-Tejedor, E.; Bullido, M.J.; Valdivieso, F.; Barreiro, P. 2002: APOE genotype in cerebrovascular disease and vascular dementia. Journal of the Neurological Sciences 203-204: 173-176
Chapman, J.; Vinokurov, S.; Achiron, A.; Karussis, D.M.; Mitosek Szewczyk, K.; Birnbaum, M.; Michaelson, D.M.; Korczyn, A.D. 2000: APOE genotype is a predictor of long-term progression of disability in patients with multiple sclerosis. Neurology 54(7 Supp 3): A348-A349
Song, Y.; Liu, S. 2003: APOE genotypes and risk of coronary heart disease A meta-analysis of population studies. Circulation 108(17): IV726
Perez Tur, J.; Crook, R.; Hardy, J.; Borgaonkar, D.S. 1999: APOE haplotype segregating with late-onset familial Alzheimers disease for 200 years. American Journal of Human Genetics 65(4): A484
Akanji, A.O.; Fatania, H.; Al Radwan, R.; Al Shammri, S. 2003: APOE polymorphism and lipoprotein levels in a Gulf Arab population. Clinical Chemistry 49(S6): A162
Araki, S.I.; Koya, D.; Makiishi, T.; Kashiwagi, A.; Haneda, M. 2003: APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes mellitus Result of the prospective observational follow-up Study. Diabetes 52(Suppl 1): A183
Nicodemus, K.K.; Allen, C.; Roses, A.D.; Saunders, A.M.; Small, G.; Schmechel, D.; Conneally, P.M.; Haines, J.L.; Gilbert, J.G.; Vance, J.M.; Pericak Vance, M.A. 2002: APOE promoter region SNPs, APOE genotype, and risk of Alzheimer disease in cases, controls, and families. American Journal of Human Genetics 71(4 Suppl): 471
Li, Y.J.; Pericak Vance, M.A.; Haines, J.L.; Siddique, N.; Mckenna Yasek, D.; Martin, E.R.; Hung, W.Y.; Sapp, P.; Allen, C.I.; Chen, W.; Hosler, B.; Saunders, A.M.; Dellefave, L.; Brown, R.H.Jr.; Siddique, T. 2002: APOE promoter region is associated with age at onset of amyotrophic lateral sclerosis. American Journal of Human Genetics 71(4 Suppl): 450
Rebeck, G.W.; Growdon, W.B.; Deng, A.; Cheung, B.S.; Greenberg, S.M.; Hyman, B.T. 1999: APOE promoter/enhancer polymorphisms and APOE allele expression are independent of Alzheimer disease status. Society for Neuroscience Abstracts 25(1-2): 1058
Smart, M.C.; Dedoussis, G.; Louizou, E.; Yannakoulia, M.; Drenos, F.; Papoutsakis, C.; Maniatis, N.; Humphries, S.E.; Talmud, P.J. 2010: APOE, CETP and LPL genes show strong association with lipid levels in Greek children. Nutrition Metabolism and Cardiovascular Diseases: Nmcd 20(1): 26-33
Arciniegas, D.B.; Topkoff, J.L.; Filley, C.M.; Adler, L.E.; Ricketts, K.A.; Spector, E.B. 2002: APOE-epsilon4 in association with persistant neurocognitive impairment after traumatic brain injury. American Journal of Human Genetics 71(4 Suppl): 469
Croucher, P.I.; Shipman, C.M.; Perry, M.; Russell, G.G.; Camp, B.V.; Niesor, E.J.; Bentzen, C.L.; Vanderkerken, K. 2002: APOMINETM, a Novel Inhibitor of the Mevalonate/Isoprenoid Pathway, Promotes Apoptosis of Myeloma Cells In Vitro and Is Associated with a Modulation of the Myeloma Disease In Vivo. Blood 100(11): Abstract No. 3209
Mcphie, D.L.; Hines Peralta, A.U.; Pratt, K.G.; Neve, R.L. 1999: APP and PAK3 interact to mediate apoptosis in neurons. Society for Neuroscience Abstracts 25(1-2): 2127
Confaloni, A.M.; Crestini, A.; Campeggi, L.M.; Calamandrei, G.; Ricceri, L. 2000: APP and presenilin expression in cortex and hippocampus of rats after neonatally-induced cortical cholinergic hypoactivity. European Journal of Neuroscience 12(Suppl 11): 213
Davies, P.; Debernardis, J.; Espinoza, M.; Stahl, M.; Vianna, C. 2000: APP and tau phosphorylation in Alzheimers disease. Brain Pathology 10(4): 493
Fernandez, H.L.; Chen, M. 1999: APP normal processing is regulated by Ca2+ signaling. Society for Neuroscience Abstracts 25(1-2): 596
Zhang, J.; Watson, D.; Selkoe, D.J. 1999: APP sequence requirements for gamma-secretase recognition and cleavage. Society for Neuroscience Abstracts 25(1-2): 597
Franklin, S.R.; Goodwin, A.; Oostveen, J.; Buhl, A.; Mcarthur, R.A. 2000: APP-overexpressing transgenic mice are not impaired in acquisition of an olfactory discrimination. Journal of Psychopharmacology 14(3 Suppl): A52
Pradier, L.; Czech, C. 1999: APP/presenilin interaction Mapping and modelization in vitro. Society for Neuroscience Abstracts 25(1-2): 1300
Czech, C.; Dreisler, S.; Reboul, S.; Pradier, L. 1999: APP/presenilin interaction The amino-terminus of presenilin 2 is able to interact with Abeta42 in vitro. Society for Neuroscience Abstracts 25(1-2): 1600
Hardy, J.A.; Chartier Harlin, M C.; Goate, A.M.; Owen, M.J.; Mullan, M.J. 1999: APP70 mutant in Alzheimers disease. Official Gazette of the United States Patent and Trademark Office Patents 1220(1): 492
Bonci, Desiree; Felli, Nadia; Hahne, Michael; Peschle, Cesare; De Maria, Ruggero 2003: APRIL is an autocrine growth factor for megakaryocytes. Blood 102(11): 140b
Gaillard, C.; Pethe, C.; Moffatt, B.; Laloue, M. 1999: APRT deficiency in Arabidopsis thaliana results from a mutation in the gene APT1. Biologia Plantarum 42(Suppl ): S117
Belloni, F.L.; Lowy, M.; Matyas, M.L. 2003: APS Archives of Teaching Resources a collegial sharing resource for physiology teachers. FASEB Journal 17(4-5): Abstract
Baleva, M.P.; Nikolov, K.V. 2002: APS The effect of the pendulum. Lupus 11(9): 595
Harris, E.N.; Pierangeli, S.; Gharavi, A. 2002: APS Unsolved mysteries. Lupus 11(9): 571
Ziporen, L.; Levi, Y.; Rauova, L.; Shoenfeld, Y. 1999: APS and HIT Is there crossreactive epitopes and common mechanisms?. Journal of Autoimmunity (Suppl ): 88
Macejova, Z.; Szilasiova, J.; Trejbal, D. 2002: APS and its clinical manifestations. Lupus 11(9): 593
Latino, J.O.; Bierfass, G.R.; Carballo, O.G.; Fernandez Romero, D.S.; Paolini, M.V.; Prada, M.E.; Scher, U.; Pesaresi, M.; Di Lonardo, A.M. 2002: APS and pregnancy A retrospective study. Lupus 11(9): 614
Maina, A.; Donvito, V.; Balbi, L. 2002: APS and pregnancy A seven year experience. Lupus 11(9): 611
Cathebras, Pascal; Roy, Michel; Baccot, Sylvianne; De Filippis, Jean Pierre 2000: APS and/or HELLP syndrome Thrombotic microangiopathy with liver, gut, and bone infarction during pregnancy. Journal of Autoimmunity 15(2): A67
Falcini, F.; Cimaz, R.; Avcin, T. 2002: APS can occur in children, too Proposal for guidelines in the pediatric age. Lupus 11(9): 557
Katzav, A.; Pick, C.G.; Korczyn, A.D.; Blank, M.; Shoenfeld, Y.; Chapman, J. 2002: APS exacerbates cognitive impairment in an APP mouse model of Alzheimers disease. Lupus 11(9): 604
Hadacova, I.; Vavrincova, P.; Hladikova, E.; Sukova, M.; Vavrinec, J. 2002: APS in children with systemic autoimmune disease. Lupus 11(9): 555
Kljukvina, N.G.; Shekshina, S.V.; Baranov, A.A.; Nassonov, E.L. 2002: APS in male lupus. Lupus 11(9): 631
Farquharson, R.G.; Quenby, S.M.; Greaves, M. 2002: APS in pregnancy A controlled treatment trial. Lupus 11(9): 580
Levy, R.A.; Jesus, N.R.; Almeida, M.V.L.; Albuquerque, E.M.N.; Trajano, A. 2001: APS in pregnancy Favorable outcome with coumadin treatment from week 14 to 36. Lupus 10(Suppl 1): S89
Mccarty, G.A.; Cason, T.E.; Scully, K.W. 2002: APS in the UVA clinical data repository 1996-2001. Lupus 11(9): 609
Ugalde, J.; Egurbide, V.; Ruiz Irastorza, G.; Aguirre, C. 2002: APS is a major cause of chronic damage in patients with SLE. Lupus 11(9): 595
Daugas, E.; Nochy, D.; Caudwell, V.; Jacquot, C. 2002: APS nephropathy in patients with isolated antiphospholipid antibodies. Lupus 11(9): 622
Vacca, A.; Littera, R.; Carta, M.; Piras, E.; Oppi, S.; Arras, M.; Marongiu, F.; Parodo, G.; La Nasa, G.; Faa, G.; Contu, L. 2000: APS syndrome in a patient with non-Hodgkin lymphoma of the marginal zone Effectiveness of chemoimmunotherapy with Fludarabina and Rituximab. Journal of Autoimmunity 15(2): A50
Cherniack, A.D.; Coulter, S.M.; Bose, A.; Karkut, C.J.; Czech, M.P. 1999: APS, a novel insulin receptor substrate and binding partner highly expressed in muscle and fat. Diabetes 48(Suppl 1): A326
Perheentupa, J. 2002: APS-I/APECED: the clinical disease and therapy. Endocrinology and Metabolism Clinics of North America 31(2): 295-320 Vi
She, Jin Xiong 1999: APS1 The monogenic autoimmunity of aire. Journal of Autoimmunity (Suppl ): 33
Titus, T.; Badet, L.; Mc Shane, P.; Smith, R.A.G.; Gray, D.W.R. 2001: APT070 a novel membrane targeted C3 convertase inhibitor, attenuates islet damage in an in vitro model of hyperacute pancreatic islet xenograft rejection. Molecular Immunology 38(2-3): 125
Shaw, J.; Bott, M.; Johnson, R.; Ivor, L.; Light, J.; Mauricio, M.; Spencer Covill, S. 2002: APTIMA CT assay Chlamydia trachomatis diagnostic or confirmation applications in one assay. International Journal of STD and AIDS 13(Suppl 1): 37
Pate, M.S.; Hook, E.W.IIi; Martin, D.H.; Willis, D.; Schachter, J.; Gaydos, C.; Quinn, T.C.; Weissfeld, A.; Ferrero, D. 2001: APTIMA combo 2 A new assay for detection of C trachomatis in men. International Journal of STD and AIDS 12(Suppl 2): 116
Bott, M.; Bixby, T.; Castillo, M.; Light, J.; Smith, M.; Spencer Covill, S.; Turner, S.; Watson, M.; Williams, R.; Shaw, J. 2001: APTIMATM Combo 2 analytical performance with C trachomatis and N gonorrhoeae. International Journal of STD and AIDS 12(Suppl 2): 97-98
Zoran, M.; Coen, D.; Bronic, A. 2001: APTT in patients on LMWH prophylaxis. Clinical Chemistry and Laboratory Medicine 39(Special Suppl): S269
Toh, C.H. 1999: APTT revisited: detecting dysfunction in the hemostatic system through waveform analysis. Thrombosis and Haemostasis 82(2): 684-687
Toh, C.H.; Downey, C.; Hargreaves, D.; Robin, N. 1999: APTT waveform analysis and prediction of mortality in the critical care setting. British Journal of Haematology 105(Suppl 1): 47
Haj Ichya, S.; Sherer, Y.; Blank, M.; Shoenfeld, Y. 2002: APTs induce thrombosis in an animal model of APS. Lupus 11(9): 550
Raikhlin, N.; Smirnova, E.; Probatova, N.; Bebezov, B.; Badaljan, X.; Tschistjakova, O.; Bronstein, M.; Bukaeva, I.; Baronin, A. 2001: APUD-system tumours Ultrastructural diagnosis and prognosis. Virchows Archiv 439(3): 389-390
Ravaglia, S.; Bini, P.; Chimento, P.; Costa, A.; Moglia, A. 2003: APoE genotype and nongenetic risk factors Interactions in Alzheimers disease. European Journal of Neurology 10(Suppl 1): 235
Etnier, J.L.; Sibley, B.A.; Caselli, R.J.; Tessier, D. 2003: APoE-4 genotype and aerobic fitness as predictors of cognitive decrements in older women. Medicine and Science in Sports and Exercise 35(5 Suppl): S25
Hudson, R.A. 2000: AQ10 biofungicide A case study in the commercialization of biological control agents. Phytopathology 90(6 Suppl): S101
Agren, J.; Zelenin, S.; Hakanson, M.; Eklof, A.C.; Nielsen, S.; Aperia, A.; Sedin, G. 2000: AQP 3 expression in perinatal rat skin Relation to age, skin barrier function and antenatal corticosteroid treatment. Acta Physiologica Scandinavica 170(4): A44-A45
Valenti, G.; Procino, G.; Annamaria, D'alessandro; Francesco, A.; Laera, A.; Rigamonti, W.; Della Vella, M.; Montini, G.; Zacchello, G.; Svelto, M.; Murer, L. 2003: AQP2 downregulation in human congenital obstructive nephrouropathy. Journal of the American Society of Nephrology 14(Abstracts Issue): 310A
Marchini, G.; Kankes, K.; Stabi, B.; Lonne Rahm, S.; Nielsen, S. 2003: AQP3-expressing immune cells in erythema toxicum neonatorum A possible role in immunosurveillance at birth. Pediatric Research 53(4 Part 2): 363A
Nejsum, L.N.; Kwon, T.H.; Fumagelli, O.; Frokiaer, J.; Agre, P.; Menon, A.G.; Krane, C.M.; Nielsen, S. 2001: AQP5 is present in the apical plasma membrane of rat and mouse sweat glands, and mice deficient of AQP5 have significantly reduced sweat secretion. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 62A
Colombo, C.; Barbetti, F.; Pavan, W.; Reitman, M. 2003: AQTLon chromosome 1 regulates glucose level, triglyceride level, liver weight and body weight in lipoatrophic mice. Diabetes 52(Suppl 1): A249
Nelson, R.M.; Hainsworth, A.H.; Lambert, D.G.; Jones, J.A.; Murray, T.K.; Cross, A.J.; Green, A.R. 2000: AR-A008055, a clomethiazole analogue, is neuroprotective in a global ischaemia model in vivo and inhibits ischaemia-induced glutamate release in vitro. British Journal of Pharmacology 131(Proceedings Suppl December): 204P
Warmoth, K.; Trujillo, K.A.; Ruzek, E.; Glen, R.; Smith, J.; Thomsen, W.; Behan, D.P.; Chalmers, D.T. 1999: AR116,102, a novel high affinity 5HT2A receptor inverse agonist with in vivo efficacy. Society for Neuroscience Abstracts 25(1-2): 1201
Ueda, T.; Yamaguchi, M.; Uchimiya, H.; Nakano, A. 2001: ARA6, a plant-unique RAB/YPT GTPase involved in the regulation of endocytic function in Arabidopsis thaliana. Cell Structure and Function 26(5): 396
Zhao, L.; Hu, Y.; Chong, K.; Wang, T. 2010: ARAG1, an ABA-responsive DREB gene, plays a role in seed germination and drought tolerance of rice. Annals of Botany 105(3): 401-409
Guo, D.F.; Hamet, P.; Orlov, S.N. 2000: ARAP1, a novel angiotensin II type 1 receptor associated protein, binds and recycles the receptor to the plasma membrane. Canadian Journal of Cardiology 16(Suppl F): 125F
Shelke, R.R.J.; Dirks, A.J.; Leeuwenburgh, C. 2002: ARC an inhibitor of apoptosis is expressed in the rat brain and is increased with caloric restriction. FASEB Journal 16(4): A140
Li, J.; Li, P.; Von Harsdorf, R. 2001: ARC blocks p53-induced cardiomyocyte apoptosis through inhibiting the activation of caspase-3 and caspase-9 but independent of cytochrome c. Circulation 104(17): 2; 293
Courtney, U.M. 2002: ARC breast cancer partners programme A psychoeducative programme for men. European Journal of Cancer 38(Suppl 3): S76-S77
Courtney, U.M. 2001: ARC breast cancer partners support programme. European Journal of Cancer 37(Suppl 6): S397
Courtney, U.M. 2001: ARC support services in cancer care in Ireland. European Journal of Cancer 37(Suppl 6): S439
Howells, R.; Calvin, J.; Karet, F.; Firth, H.; Ramaswami, U. 2001: ARC syndrome Heterogeneity in liver dysfunction. Journal of Inherited Metabolic Disease 24(Suppl 1): 151
Gissen, P.; Johnson, C.A.; Stapelbroek, J.; Mckieman, P.J.; Thompson, R.J.; Houwen, R.; Kelly, D.A.; Maher, E.R. 2003: ARC syndrome is not allelic to PFIC 1 and 2. Journal of Medical Genetics 40(Suppl 1): S64
Hofler, J.G.; Kettlety, T.R.; Wolaniuk, D.L.; Smith, S.B.; Schmidt, E.M.; Smith, G.A.; Covert, W.E.; Friese, J.A. 2004: ARCHITECT CA 15-3, a chemiluminescent assay. Clinical Chemistry 50(6, Suppl S, Part 2): A82
Kuemmerle Deschner, J.B.; Bergmann, J.; Ihle, J.; Orlikowski, T.; Dannecker, G.E. 1999: ARDIS - arthritis and rheumatism database and information system. Arthritis and Rheumatism 42(9 Suppl): S327
Stoeck, T.; Welter, H.; Seitz Bender, D.; Kusch, J.; Schmidt, H.J. 2000: ARDRA and RAPD-fingerprinting reject the sibling species concept for the ciliate Paramecium caudatum. Zoologica Scripta 29(1): 75-82
Wiedermann, F.J.; Lederer, W.; Sepp, N.; Schobersberger, W. 2001: ARDS in catastrophic antiphospholipid syndrome. Lupus 10(5): 382-383
Cerf, C.; Leroux, B.; Reynaud, P.; Duvaldestin, P.; Dhonneur, G. 1999: ARDS risk-factors after pulmonary contusions. Anesthesiology 91(3A): A231
Zhang, T.; Kruys, V.; Huez, G.; Gueydan, C. 2002: ARE-mediated translational control Complexity and multiple activities of trans-activating factors. Biochemical Society Transactions 30(5): A116
Yoshida, T.; Fujita, Y.; Sayama, H.; Kidokoro, S.; Maruyama, K.; Mizoi, J.; Shinozaki, K.; Yamaguchi-Shinozaki, K. 2010: AREB1, AREB2, and ABF3 are master transcription factors that cooperatively regulate ABRE-dependent ABA signaling involved in drought stress tolerance and require ABA for full activation. Plant Journal: for Cell and Molecular Biology 61(4): 672-685
Mcpherson, E. 2000: AREDYLD syndrome with focal segmental glomerulosclerosis. Genetics in Medicine 2(1): 82
Cockcroft, S.; Jones, D. 1999: ARF, a multi-functional GTPase as a co-ordinator of membrane traffic - Is ARF-regulated phospholipase D the answer to everything?. Biochemical Society Transactions 27(3): A75
Sherr, C.J.; Quelle, D.E. 2001: ARF-p19, a novel regulator of the mammalian cell cycle. Official Gazette of the United States Patent and Trademark Office Patents 1242(2)
Sherr, C.J.; Zindy, F.; Kamijo, T.; Weber, J.D.; Eischen, C.M.; Diehl, J.A.; Randle, D.; Chong, M.; Cleveland, J.L.; Mckinnon, P.J.; Zambetti, G.; Roussel, M.F. 1999: ARF-p53 pathway in tumor surveillance. Proceedings of the American Association for Cancer Research 40: 775
Spang, A. 2002: ARF1 regulatory factors and COPI vesicle formation. Current Opinion in Cell Biology 14(4): 423-427
Palacios, F.; D'souza Schorey, C. 2000: ARF6 regulates adherens junction assembly in epithelial cells. Molecular Biology of the Cell 11(Suppl): 115a-116a
Bettandorff, J.A.; Delaney, K.A.; Radhakrishna, H. 2000: ARF6 regulates the non clathrin-dependent trafficking of m2 muscarinic acetylcholine receptors. Molecular Biology of the Cell 11(Suppl): 507a-508a
Galkin, V.E.; Orlova, A.; Koleske, A.J.; Egelman, E.H. 2004: ARG kinase uses multiple modes to bind F-actin. Biophysical Journal 86(1): 68a
Varret, M.; Abifadel, M.; Villeger, L.; Robin, A.; Allard, D.; Devillers, M.; Rabes, J.P.; Junien, C.; Boileau, C. 2002: ARH and HCHOLA3 Two different genes at 1p both implicated in familial hypercholesterolemia. American Journal of Human Genetics 71(4 Suppl): 443
Zlotogora, J. 2002: ARH mutations and hypercholesterolaemia in Sardinia. Lancet 360(9338): 1024; Author Reply 1024
Xu, F.; Yu, Y.H. 2000: ARHI , an imprinted tumor suppressor gene, was lost in bladder and prostate carcinomas. Proceedings of the American Association for Cancer Research 41: 779
Bao, J.J.; Le, X.F.; Wang, R.Y.; Andreeff, M.; Yu, Y.; Bast, R.C. 2002: ARHI induces apoptosis through a caspase-independent pathway. Proceedings of the American Association for Cancer Research 43: 620
Yu, Y.; Xu, F.J.; Xia, W.; Zhao, S.; Peng, H.Q.; Luo, R.Z.; Long, Y.; Parlow, A.F.; Hung, M.C.; Bast, R.C. 2000: ARHI inhibits the production of PRL and progesterone, induces the defects of ovary and mammary gland development in transgenic mice. Proceedings of the American Association for Cancer Research 41: 227
Yu, Y.H.; Peng, H.Q.; Xu, F.J.; Fang, X.J.; Zhao, S.L.; Huang, Z.; Thornton, A.; Devers, M.; Kuo, W.L.; Gray, J.W.; Mills, G.B.; Bast, R.C.Jr 1999: ARHI is an imprinted tumor suppressor gene on 1p31. Proceedings of the American Association for Cancer Research 40: 546
Luo, R.Z.; Xianjun, F.; Marquez, R.; Liu, S.Y.; Mills, G.B.; Liao, W.S.L.; Yu, Y.; Bast, R.C.J. 2003: ARHI is an unusual Ras family member that inhibits growth and constitutively binds GTP in resting cells. Proceedings of the American Association for Cancer Research 44: 594
Lockey, R.F. 2001: "ARIA": global guidelines and new forms of allergen immunotherapy. Journal of Allergy and Clinical Immunology 108(4): 497-499
Klossek, J.; Neukirch, F.; Gehanno, P.; Bodez, T.; Liard, F.; Janin, N.; Bousquet, J. 2004: ARIA guidelines for allergic rhinitis in specialist practices A randomized controlled trial with ebastine. Journal of Allergy and Clinical Immunology 113(2 Suppl): S26
Kortschak, R.D.; Tucker, P.W.; Saint, R. 2000: ARID proteins come in from the desert. Trends in Biochemical Sciences 25(6): 294-299
Kotaja, N.; Aittomaki, S.; Silvennoinen, O.; Palvimo, J.J.; Janne, O.A. 2000: ARIP3 and other PIAS proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Molecular Endocrinology 14(12): 1986-
Rouleau, N.; Moilanen, A.M.; Palvimo, J.J.; Janne, O.A. 2004: ARIP4 gene and protein. Official Gazette of the United States Patent and Trademark Office Patents 1279(3)
Murray, T.K.; Wiernicki, T.R.; Mccarty, D.R.; Hicks, C.A.; Dell, C.P.; Patrick, K.E.; Ward, M.A.; Osborne, D.J.; Roman, C.R.; Lodge, D.; Fleisch, J.H.; Singh, J.; O'neill, M.J. 1999: ARL17477, a selective neuronal nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Society for Neuroscience Abstracts 25(1-2): 1842
Feltner, M.E. 2003: ARM action alters bicep femoris and rectus femoris activity during countermovement vertical jumps. Medicine and Science in Sports and Exercise 35(5 Suppl): S323
Karimi, M.; Porceddu, A.; Mironov, V.; Van Montagu, M.; Inze, D.; Gheysen, G. 1999: ARM1 Application for engineered resistance to plant-parasitic nematodes. Mededelingen van de Faculteit Landbouwwetenschappen - Rijksuniversiteit Gent 64(5B): 439-442
Montalescot, G.; Drouet, L. 2001: ARMADA study A randomized comparison of enoxaparin, dalteparin and unfractionated heparin on markers of cell activation in patients with unstable angina. European Heart Journal 22(Abstract Suppl): 663
Richer, S.P. 1999: ARMD Pilot environmental intervention data. IOVS Investigative Ophthalmology and Visual Science 40(4): S313
Richer, S.P.; Statkute, L.; Stiles, W.; Rudy, D.R.; Karofty, K. 2000: ARMD-serum iron, % transferrin and ferritin data. IOVS Investigative Ophthalmology and Visual Science 41(4): S159
Lui, H.M.; Naumovski, L. 2002: ARMER protects cells against apoptosis. Proceedings of the American Association for Cancer Research 43: 998
Dworniczak, B.; Vorobyov, E.; Kondrashov, A.; Juelich, A.; Dockhorn Dworniczak, B.; Horst, J. 1999: ARMS Identification of novel differentially expressed genes. Modern Pathology 12(1): 10A
Callaghan, K.; Howes, N.; Greenhalf, W.; Neoptolemos, J.P.; Fox, J.C. 1999: ARMS detection in real time of under- represented mutant K-ras sequence in patients at risk of pancreatic cancer. British Journal of Cancer 80(Suppl 2): 83
Altschuler, Y.; Santy, L.; Frank, S.; Avrahami, D.; Li, Y.W.; Casanova, J.; Mostov, K. 2000: ARNO and ARF6 regulate endocytosis at the apical surface of polarized epithelial cells. Molecular Biology of the Cell 11(Suppl): 324a-325a
Greenwood, R.; Nicholas, R. 2002: ARO1 multifunctional polypeptide of Candida albicans. Official Gazette of the United States Patent and Trademark Office Patents 1255(2)
Mueller, A.; Moser, M.; Leder, S.; Kluge, R.; Joost, H.G.; Schuermann, A. 2001: ARP is essential for the embryonic development of mice. Naunyn-Schmiedeberg's Archives of Pharmacology 363(4): R59
Eldor, A.; Grisaru, D.; Deutsch, V.; Shapira, M.; Sternfeld, M.; Melamed Book, N.; Kaufer, D.; Galyam, N.; Lessing, J.B.; Soreq, H. 2000: ARP, a 26-residue peptide cleaved from acetylcholinesterase, modulates blood cell composition under stress and acts as a hematopoietic growth promoting factor. Acta Haematologica (Basel) 103(Suppl 1): 2
Swanson, J.C. 2002: ARPAS animal care certification program. Journal of Dairy Science 85(Suppl 1): 168
Tao, W.; Rein, D.H.; Dean, B.J.; Stabila, P.F.; Goddard, M.B.I. 2002: ARPE-19 as a platform cell line for encapsulated cell-based delivery. Official Gazette of the United States Patent and Trademark Office Patents 1256(4)
Nurnberger, J.; Miller, K.J.; Wang, J.; Sanford, M.; Bacallao, R.L.; Phillips, C.L. 2001: ARPKD and inversin Isoforms and cellular distributions. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 542A